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ABSTRACT 
Reduced glutathione, GSH, artificially induces the signature feeding behavior in 
the early-evolved metazoan, Hydra vulgaris. Evidence has shown that the mouth 
opening response is prolonged by the inhibitory neurotransmitter, GABA. By making 
extracellular recordings of a detached reduced-tentacle hypostome, it is possible to 
record the electrical activity produced by GSH and to observe the effects of the 
inhibitory neurotransmitter, gamma-amino-butyric acid (GABA), the GABAB agonist 
(baclofen) and the GABAB antagonist, (phaclofen).  
When an electrode is placed on the mouth of the hypostome, thus blocking the 
mouth opening, and the ligands are placed in the bath surrounding the base of the 
hypostome, the following effects are observed: GSH increased small-uncorrelated 
hypostomal pulses (SUHPs), medium-uncorrelated hypostomal pulses (MUHPs), 
pacemaker bursting pulses (PBPs) and pulses per pacemaker bursting pulse (P/PBPs). 
Although GABA per se produced no effect when administered with GSH, baclofen 
caused an increase in SUHPs, while phaclofen per se caused a decrease; 
coadministration of baclofen and phaclofen mutually cancelled their individual effects.  
This suggests that at least some of the SUHPs might be GSH neuronal impulses 
having metabotropic (GABAB) receptor involvement. GSH coadministered with 
baclofen and phaclofen caused a decrease in MUHPs and rhythmic potentials (RPs); 
GABA administered with GSH produced no effect on MUHPs and RPs.   
 When the ligands were placed within the pipette at the mouth (exposing the 
mouth opening to ligands and blocking the proximal portion of the hypostome), the 
following effects were observed: GSH increased MUHPs and decreased extra-large 
  
uncorrelated hypostomal pulses (XLUHPs) and P/PBPs; this comports with the 
previously observed GSH induced cone-formation of the hypostome, now 
hypothesized to be reflected in the increase MUHPs (which may be muscle pulses) 
and the concurrent inhibition of body contraction (considered to be mediated by 
XLUHPs and PBPs). This effect was abolished by GABA, which increased the 
frequency of the large pulses, but not mimicked by baclofen nor counteracted by 
phaclofen, both of which also decreased in the large pulses.  This suggests that GABA 
inhibition of GSH activity might also involve the action of GABA on its ionotropic 
receptors and that GABAB receptors exist on the excitatory effector circuits. GSH 
administered with baclofen caused a decrease in SUHPs.   
In general, GSH administered alone, GSH and GABA, GSH and phaclofen, GSH 
and baclofen and GSH coadministered with baclofen and phaclofen caused 
significantly increased activity when applied directly to the apex of the hypostome, 
indicating that both GSH and GABAB receptors are concentrated in or around the 
hypostomal apex.   
Although GABA combined with GSH produced no significant differences in the 
frequency of any of the parameters measured in the bath-applied method, 
coadministration increased LUHPs, XLUHPs, PBPs and RPs in the pipette-applied 
method—suggesting prolongation of mouth opening. The results support the 
behavioral observations that GABA inhibits the cessation of the GSH-induced feeding 
response and indicates that GSH and GABA receptors are differentially distributed in 
the hypostome.    
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EFFECTS OF GABAB RECEPTOR LIGANDS ON THE GSH-INDUCED 
ELECTRICAL ACTIVITY OF THE HYPOSTOME IN HYDRA 
 
INTRODUCTION 
Hydra is an early-evolved metazoan found in small lakes and ponds, and is 
considered the quintessential example of an animal with a simple nervous system. 
Hydra’s long, cylindrical body column has two main body layers consisting of an 
ectoderm and endoderm separated by a gel-like mesoglea.  Distributed along the 
ectoderm lays a simple nervous system composed of interconnecting, synapsing 
neurons (Hadzi, 1909; Koizumi, 2007; Kinnamon and Westfall, 1981).  The two body 
layers meet at the apex of the mouth surrounded by a whorl of tentacles amid 
specialized stinging cells called cnidocytes—used for capturing prey.  Its feeding 
behavior consists of tentacle writhing, longitudinal body contractions, and mouth 
opening/closing.  Nonetheless, the neuronal mechanisms controlling the patterned 
behavior have not been fully described.    
Numerous sensory cells are involved in hydra’s feeding behavior.  One of the 
most intriguing physiological phenomena is the chemical induction of a complex 
feeding pattern of behavior in the fresh water polyp, Hydra vulgaris by GSH 
(Loomis, 1955).  The artificially induced GSH feeding behavior of hydra is a well-
defined quantifiable mechanism and is one of the most familiar chemosensory 
behaviors to date.  Specifically, used to study the dynamics of receptor binding 
(Lenhoff and Bovaird, 1961) and the behavioral physiology of a ligand-induced 
feeding behavior.  After piercing its prey (with cnidocytes on hydra’s tentacles), the 
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captured releases the tripeptide glutathione (GSH).  Tentacle writhing, mouth 
(hypostome) opening, and body contractions result and are the key features of this 
synchronized behavior (Loomis and Lenhoff, 1956; Lenhoff et al., 1961; Bellis et al., 
1992; Grosvenor et al., 1996; Pierobon et al., 1995; Kass-Simon et al., 2003).  The 
hypostome maximally expands to accompany the size of homogenate and the prey is 
ingested along the endoderm-lined gut.  Eventually, hydra regurgitates the quarry and 
closes the mouth; the feeding behavior lasts approximately 30 minutes.  The signature 
role and specific function of receptors and organelles involved during a centrally 
correlated behavior (such as the ability to capture, ingest, and regurgitate prey) has 
yet to be understood; it is important to identify the existence and the behaviorally-
correlated output of these receptors and organelles in hydra’s feeding.   
Experiments to localize the GSH receptors have been carried out by many 
investigators.  After approximately one-two minutes of GSH exposure, the mouth will 
rapidly open and remain open until an inhibitory stimulus is initiated.  The feeding 
response is quickly terminated by the removal of GSH and application of KCl and 
veratridine (Pierobon et al., 2004).  The GSH-induced feeding behavior is also 
antagonized by L-glutamic acid (Lenhoff and Bovaird, 1961).  Homogenized 
cnidocyte-fractions of hydra tentacles with radiolabeled glutamate inhibited GSH 
binding (Venturini, 1987) and it was believed that glutamate was a competitive 
inhibitor of GSH binding at the GSH receptor site.  However, other studies showed 
that glutamate had bound to its own receptors and that GSH was still binding to its 
receptor site (Bellis et al., 1991; Grosvenor et al., 1992).   Thus, there may be a site on 
the glutamate receptor, specifically for GSH binding.   
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Neuronal gap junctions indicated the first ultrastructural evidence of electrical 
synapses in Hydra’s nervous system and more frequently occurring, chemical 
synapses produced by the same neuron in the hypostome (Westfall et al., 1980).  
These chemical and electrical synapses are similar to indirect and direct, interneuronal 
communication between neurons in the brain (Meier and Dermietzel, 2006).   Synaptic 
connectivity between the hypostome and the tentacles is due in part to multiple 
neuronal clusters found between the hypostome-tentacle junction (Kinnamon and 
Westfall, 1982)—similar to ganglia found in the mammalian nervous system.  
Chemical synapses and gap junctions between neurons of the hypostome and tentacle 
junction may be involved in eliciting the feeding behavior from mouth opening to 
tentacle writhing (Kinnamon and Westfall, 1982). The simultaneous opening of the 
mouth and tentacle writhing is a signature behavior that may be under specific 
neuronal control. Kass-Simon (1972) placed electrodes just near the tentacles and the 
original electrical findings indicated that there were impulse initiation sites at the base 
of the tentacles.  Thus, the newly observed proximal nerve net at the base of the 
hypostome and the distal nerve net at the apex of the hypostome may be involved in 
coordinating hydra’s feeding response (Hufnagel and Kass-Simon, unpublished).   
Evidence of chemoreception, elicited by hydra’s response to GSH, can be 
found when hydra is exposed to concentrations ranging from high nanomolar to low 
micromolar of GSH (Lenhoff, 1961; Bellis et al., 1992).  A quantitative assay of 
mouth opening duration (Lenhoff, 1961) led to characterization of the glutathione 
chemoreceptor; the GSH-induced feeding response (Pierobon et al., 1995) was 
quantified by duration of mouth opening that lasted 10 minutes with1 µm GSH.  
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Maximal duration of mouth opening occurs at 5 µM GSH with a 50% response at 1 
µM GSH (Grosvenor et al., 1996). After the 30-minute time lapse of hydra’s feeding 
behavior, the mouth will slowly close.  However, evidence has shown that the major 
invertebrate inhibitory neurotransmitter, gamma-immuno butyric acid (GABA) at 100 
µM, prolonged the duration of the response in which the time for the mouth to close 
was increased (Pierobon et al., 1995).  In addition, the major excitatory 
neurotransmitter in the mammalian nervous system, glutamate has been shown to be 
involved in this coordinated effect by increasing tentacle activity in the tentacle pulse 
pacemaker system (TPs) (Kay and Kass-Simon, 2008); the GSH-induced feeding 
behavior is dose dependent, saturable, and antagonized by L-glutamic acid (Lenhoff 
and Bovaird, 1961; Bellis et al., 1991). 
The hypostome (mouth) plays a signature role in executing this behavior. 
Numerous sensory nerve cells surround the dome of the hypostome and the question 
that has yet to be answered is what do these nerves do to open and close the mouth? 
Labeling with L96+ antibody has indicated a specialized endodermal tissue type 
separating the ectoderm from the endoderm in this specialized structure (Technau et 
al., 1995).  The hypostome’s ability to extend considerably during feeding behavior 
without tearing is due to this one-cell thick ring of endodermal tissue between the 
ectodermal and endodermal lining of the mouth (Technau et al., 1995).  Scanning 
electron microscopy of the internal lining of the hypostome has revealed that it has 
endodermal cylindrical microvilli along the inside of the hypostome with protruding 
flagella and microvilli extending towards the hypostomal, tentacle region (Wood, 
1979).  The microvilli in addition to the mucous producing endoderm along the inside 
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lining of the mouth may be chemoreceptive sites that initiate chemically mediated 
behaviors (Kass-Simon and Hufnagel, 1992; Slautterback, 1967).  In addition, an even 
distribution of multiple synpases between epitheliomuscular cells and neurons were 
found in the region between the hypostome and the tentacle area in the oral epidermis 
(ectoderm)—suggesting delicate muscular control of the mouth opening/closing 
behavior and its ability to engulf prey (Kinnamon and Westfall, 1982).      
Previous studies identified a circular nerve ring surrounding the hypostome 
(Westfall et al., 1974; Grimmelikhuijzen et al., 1985; Koizumi et al., 1992).  However, 
recent evidence has identified two centralized nerve rings found within the 
hypostome—the proximal and distal nerve rings of the ectodermal layer representing a 
simplified model of the mammalian brain; they are connected to one another by 
radially anastomosing neurons (Hufnagel and Kass-Simon, unpublished).  The 
proximal nerve ring has been identified to run between, and slightly below the 
tentacles (Hufnagel and Kass-Simon, unpublished) and is presumed responsible for the 
body-contraction pacemaker impulses (Passano and McCullough, 1964; Kass-Simon, 
1972, 1973).  The proximal nerve ring receives neuronal and behaviorally-correlated 
input from impulses arising in the tentacle pacemaker conducting system (Rushforth 
and Burke, 1971; Kass-Simon, 1972, 1973; Hufnagel et al., 2009).  There is also 
recent evidence of an anti-GABAB receptor antibody labeling of the proximal nerve 
ring suggesting the existence of GABAB receptor proteins occurring in Hydra  (Kass-
Simon and Hufnagel, unpublished).   Although the newly observed distal nerve ring, 
located at the tip of the hypostome, is a loosely organized ring of interconnecting 
neurons and is hypothesized to be responsible for coordinating hydra’s feeding 
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response—has not been found to label with anti-GABAB receptor antibody (Hufnagel 
and Kass-Simon, unpublished).  However, labeling of the endodermal layer of the 
hypostome with anti-GABAB receptor antibody suggests possible involvement in 
hydra’s mouth opening and closing behavior during feeding (Hufnagel and Kass-
Simon, unpublished).   
Three main endogenous pacemaker systems work together to control the 
behavior of Hydra—the ectodermal contraction burst system (CBs)—located in 
between and just below the tentacles (Passano and McCullough, 1963, 1964), the 
tentacle pulse system (TP)—located in the proximal part of each tentacle (Rushforth 
and Burke, 1971; Kass-Simon, 1972, 1973), and the endodermal rhythmic potential 
system—located near the base of the hydra (Passano and McCullough, 1962; Kass-
Simon and Passano, 1978).  
During the initial stages of feeding behavior, Hydra’s tentacles writhe together.  
In the presence of 10µM GSH in whole tentacle preparations, recordings from the 
tentacles revealed that GSH inhibits the tentacle contraction pulse (TCP) system and 
induces monophasic pulses.  These pulses are suggestive of the characteristic writhing 
movement of tentacles observable during feeding behavior (Rushforth and Burke, 
1971). The TCP system produces bursts similar to that of the contraction burst system 
and sometimes precede contraction burst pulses; the interpulse interval within a burst 
of pulses decreases and then slowly increases.  GABA and glutamate receptors are 
also involved in modulating pacemaker activity in hydra (Kass-Simon et al., 2003).  
Initial post-feeding behavior results in an increased frequency of tentacle pulses and 
contraction bursts (Grosvenor et al., 1996).  However, GABA alone decreases the 
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number of contraction bursts (CBs) and pulses per pacemaker burst (P/PBP) among 
the ectoderm and rhythmic potentials (RPs) among the endoderm; GABA does not 
affect the tentacle pacemaker system.  The contraction burst system is conducted 
through the body column and around the hypostome—resulting in a burst of pulses 
parallel with a shortening of the body column and tentacular contractions (Kass-
Simon, 1972, 1973). The rhythmic potential system produces pulses that are 
frequently not identifiable with any overt behavior of hydra although they increase in 
frequency when the animal elongates.  They are conducted in a regular pattern, on the 
endoderm (Kass-Simon and Passano, 1978; Kass-Simon et al., 2003).  
Multiple endogenous neurotransmitters have been discovered in hydra and may 
be involved in the modulation of such an effect.  Strychnine-sensitive glycine 
receptors (glyRs) occur in hydra’s tissues and activation of these glyRs cause 
increased prolongation to the GSH-induced feeding response.  Glutamate, the major 
excitatory neurotransmitter in the mammalian nervous system, has also been reported 
in hydra’s tissues. In particular, biochemical and immunohistochemical studies have 
identified the existence of GABA in hydra’s tissues.  Pierobon et al. (1995) and 
Concas et al. (1998), report high affinity specific binding of radiolabeled GABA to 
hydra membranes—binding was displaced by the GABAA agonist, muscimol.  
Specifically, co-application of 1 µM GABA and 100 nM pentobarbital (GABAA-
receptor modulator) to hydras caused a significant increase in the response to feeding 
behavior (Pierobon et al., 2004)—suggesting that GABAA receptors may be involved 
in the prolongation of hydra’s feeding behavior.     
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Widely expressed in the human body, GABA is involved in numerous 
neurological and psychiatric functions.    Studies on membrane preparation from rat 
brain using selective drugs in pharmacology have identified at least two distinct 
classes of GABA receptor—GABAA and GABAB—differing substantially in 
electrophysiological properties (Olsen et al., 1999).  The GABAA receptor complex 
contains an integral Cl− ionophore, whereas GABAB receptors couple to Ca2+ and K+ 
channels via GTP-binding proteins (Bormann, 1988). 
If GABA is involved in prolonging the duration of the response in which the 
time for the mouth to close was increased, the question that needs to be answered is 
what are the specific receptors involved in controlling this behavior?  
Electrophysiological evidence demonstrates that GABA and glutamate differentially 
affect hydra’s pacemaker systems and appear to do so by acting upon their 
respective ionotropic receptors.  Kass-Simon et al. (2003) report strong evidence 
that GABA’s effects on the endodermal pacemaker systems are inhibitory, while 
glutamate’s effects are excitatory; this evidence is consistent with the assigned roles 
of glutamate and GABA in other systems—giving support for classical receptor-
mediated amino-acid transmission.  Evidence exists supporting the inhibitory effect 
of GABA by prolonging the GSH-induced mouth opening during feeding behavior 
(Pierobon et al., 1995).  Electrophysiological studies have shown that agonists and 
antagonists to GABA affect the electrical activity in hydra— GABAA agonists 
decreased the number of contraction bursts and rhythmic potentials; GABA 
antagonists caused an increase in the frequency of rhythmic potentials and the 
number of pulses per contraction burst (Kass-Simon and Pannaccione, unpublished; 
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Kass-Simon et al., 2003).  There is also electrophysiology evidence showing the role 
of NMDA and GABAB receptors involved in controlling nematocyst discharge in 
hydra (Scappaticci and Kass-Simon, 2008).  Nematocyst discharge was increased 
with application of baclofen (GABAB agonist) and counteracted with phaclofen 
(GABAB antagonist)—suggesting possible modulation of other chemosensory 
behaviors within hydra.  
A central problem concerning hydra’s feeding response is the question of 
whether GABAB receptors might be involved in orchestrating the GSH induced 
feeding behavior.  The main question addressed in the present study is what is the 
role of GABAB receptors in modulating the GSH electrical activity.  In order to 
determine the role of GABAB on the GSH induced impulses, GABAB agonists and 
antagonists combined with GSH were used during electrical recording exploiting the 
proximal and distal nerve rings of hydra—the bath applied method and the pipette 
filled method, respectively.  The experiments were carried out on isolated, reduced-
tentacle hypostomes.   
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MATERIALS AND METHODS  
I. Animals 
Hydra vulgaris, raised at 18 ± 1.0°C in bicarbonate versene culture solution 
(BVC) consisting of 1x10-7M NaHCO3, 1x10-6M CaCl2, 1x10-8M EDTA (Loomis and 
Lenhoff, 1956) at a pH between 6.8-7.2 were selected at random, 24 ± 2 hours after 
having been fed with brine shrimp ad liberatum.  Hydra exhibit increased contractile 
behaviors after having been fed (Passano and McCullough, 1964; Grosvenor et al., 
1996) and thus were consistently selected, prepped and used for recordings at the 
allotted time.  Hydra heads and tentacles were ablated from the body of the 
experimental animals; tentacles were allowed to fully relax to maximal expansion and 
were carefully cut below the tentacle insertion region, taking care to leave intact the 
contraction burst pacemaker region located at the origin of the tentacle insertion site; 
the excised heads were allowed to heal for 24 ± 2 hours before electrical recordings 
(Figure 1)—small regenerated tentacle buds (not exceeding 1 mm) were evident at 
time of recording (Figure 2).  
II. Recording Methods 
Electrical recordings were conducted at 22 ±	 2.0°C, under red light on a low 
setting (Dolan-Jenner Industries, Inc. Fiber-Lite 190 Lamp with a red filter).  The light 
was turned on before the start of recording.  Earlier work had indicated that red light 
did not affect the pacemaker-controlled behavior of hydra (Passano and McCullough, 
1962; 1964) and that hydras were unresponsive to red light (Wilson, 1891; Haug, 
1933).   However, recent evidence in our laboratory indicated that tentacles are 
sensitive to red light—increasing the frequency of their contractions relative to 
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darkness (Guertin and Kass-Simon, 2015).  Nonetheless, since all of the present 
experiments were conducted in constant red light, light exposure would not have 
affected our experimental results.   
The electrical recording protocol was modified from the procedures of Passano 
and McCullough, 1964, Kass-Simon et al., 2003, Ruggieri et al., 2004, Kay and Kass-
Simon, 2009.  Extracellular recordings were made with a suction electrode attached 
directly at the mouth opening of the hypostome of the hydra.  Recordings were begun 
as soon as the hypostome was attached.  Impulses from the suction electrode were 
delivered to the head stage of an AM systems, Model 3000 AC/DC differential 
amplifier, converted to digital output with Power Lab and visualized using LabChart 7 
software (AD Instruments) on a MacBook Pro.  During recording, the preparations 
were observed through a dissecting microscope at 100X magnification.   
 
III. Ligands.  The following ligands were used: reduced glutathione (GSH), GABA, 
and the GABAB agonists and antagonists, baclofen and phaclofen.  Test substances 
were made fresh at 10-fold their final concentration and were subsequently diluted.  
Two methods were used to apply ligands to the hypostome.  
a) Bath-applied Ligand: One tentacle-free hypostome was placed in a 10 mL 
petri dish with 7 mL BVC.  A suction electrode was attached over the apex of the 
mouth.   The recording protocol was as follows: a ten-minute BVC control period 
followed by a ten minute treatment period at the beginning of which 1 mL GSH at 
4x10-6 M and/or neuro-transmitter ligand was added to the bath with a 1.0 mL syringe 
(Figure 3).  Each ten-minute period was subdivided into two periods, control period 1 
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(C1) and control period 2 (C2), treatment period 1 (T1) and treatment period 2 for 
statistical analysis. The first thirty seconds of each experimental sub-period was 
omitted in the analysis to allow the preparation to adapt.  C1 (acclimation period) was 
eliminated from statistical analysis.  Thus, comparisons were made for 4.5 minutes in 
C2, T1, and T2 (Figure 4).    
b) Pipette-filled Ligand: One tentacle-free hypostome was placed in a 10 mL 
petri dish containing 7 mL BVC.  The stopcock on the electrode holder was opened 
and a test substance was drawn into the pipette tip under slight negative pressure prior 
to hypostome attachment. The stopcock was then closed, so that no liquid leaked from 
the pipette.  Visual examination of the pipette tip ensured that the fluid level within the 
pipette tip remained unchanged as the tip was placed onto a hypostome in the BVC-
containing dish.  By opening the stopcock, the slight negative pressure in the pipette 
allowed a hypostome to be attached to the pipette tip. The stopcock was then closed 
preventing further leakage and/or suctioning of BVC into the pipette tip (Figure 5).  
Recordings began as soon as the hypostome was attached and lasted for 10 minutes 
with the thirty seconds (acclimation) omitted from analysis.   The remaining recording 
time was divided into two treatment periods (T1, T2) for analysis with the first 30 
seconds from treatment period (T1) omitted.  The BVC control period, C1 and C2- 
The C1 and C2 of the bath-applied ligand experiments, at 30 sec after attachment  
(above), were used as the controls for T1 and T2, respectively.  Thus, comparisons 
were made for 4.5 minutes in C1, C2, T1, and T2 (Figure 6).   
The following agonists and antagonists were used:  L-glutathione reduced 
(GSH), gamma-amino butyric acid (GABA), baclofen, and phaclofen.  All substances 
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were purchased from Tocris Cookson Inc. (Ballwin, MO, USA), except GABA, and 
GSH, which were purchased from Sigma-Aldrich (St Louis, MO, USA).   The 
following single treatment and combination experiments in final concentrations were 
performed: GSH (1x10-6M), GSH (5x10-7M), GSH (1x10-8M), GSH (5x10-7M)+ 
GABA (1x10-6M), GSH (5x10-7M) + Phaclofen (1x10-8M), GSH (5x10-7M) + 
Baclofen (1x10-8M), GSH (5x10-7M) + Phaclofen (1x10-8M) + Baclofen (1x10-8M).  
Doses of Phaclofen, Baclofen, and GABA used in combination experiments were 
chosen from previous electrophysiology experiments (Nandivada and Kass-Simon, 
unpublished; Pierobon et al., 2003, Scappaticci et al., 2004).  
IV. Data Analysis 
As stated above, because the prolonged ten-minute treatment could have 
resulted in either desensitization, or have been necessary for the substances to take 
effect and/or reach their site of action, each ten-minute period was subdivided into two 
4.5-minute periods for data analysis.  In the bath-applied method, the first 30 seconds 
was eliminated in each sub-period to allow for acclimation—treatment 1 (T1) and 
treatment 2 (T2).  
For each ligand series, at least seven animals were used.  The following 
comparisons were made in the bath-applied method:  C2 vs. T1, C2 vs. T2, T2 vs. T1.  
The following comparisons were made in the pipette-applied method:  C1 vs. T1, C1 
vs. T2, C2 vs. T1, C2 vs. T2 and T2 vs. T1.  In the bath-applied series, each set of 
animals (in the testing periods T1 and T2) was compared against its own BVC control 
period BVC (C2).  In the pipette-filled series, each set of test periods- (T1, T2) for 7 
  
 
15 
preparations was respectively compared to the set of 7 (C1) and (C2) control periods 
of the bath-applied series as described above.   
The following parameters were measured for each 4.5-min period:  frequency of 
small uncorrelated hypostomal pulses (SUHPs, 30-300 µV), medium uncorrelated 
hypostomal pulses (MUHPs, 301-570 µV), large uncorrelated hypostomal pulses 
(LUHPs, 571-800 µV), extra-large uncorrelated hypostomal pulses (≥	 801 µV),	 
rhythmic potentials (RPs), pacemaker bursting pulses (PBPs) and pulses per 
pacemaker bursts pulse (P/PBP).  Pulses were measured from peak to peak.  PBPs and 
P/PBPs (subset of MUHPs, LUHPs and XLUHPs) were visually identified by their 
characteristic bursting pattern.  RP’s (subset of SUHPs) were identified by their 
regular recurrence pattern (Passano and McCullough, 1962; Guertin and Kass-Simon, 
2015).   
Pulses were binned using the Spike Histogram module on Lab Chart 7 (AD 
Instruments). The sub-period being analyzed (C1, C2, T1, T2) was highlighted and 
selected for analysis.  Using the spike train-setup prompt, a train parameter was 
created.  The pulses were binned using arbitrary size categories.  The pulse, spike 
detector was set to 80.1 mV, 57.1 mV, 30.1 mV, and 3.0 mV to identify the number of 
pulses including and greater than the set voltage for the selected 4.5-min period.  To 
identify the number of pulses between 30-300 µV (SUHPs), the number of pulses 
generated for 30.1 mV was subtracted from 3.0 mV.  To identify the number of pulses 
between 301-570 µV (MUHPs), the number of pulses generated for 57.1 mV was 
subtracted from 30.1 mV.  To identify the number of pulses between 571-800 µV 
(LUHPs), the number of pulses generated for 80.1 mV was subtracted from 57.1 mV.  
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To identify the number of pulses equal and greater to 801 µV (XLUHPs), the number 
of pulses generated for 80.1 mV was reported. 
Data analysis was similar to that used in previous electrophysiology studies (Kay 
and Kass-Simon, 2009; Ruggeri et al., 2004; Guertin and Kass-Simon, 2015). A 
Friedman Two-Way Analysis of Variance (FANOVA) for each parameter was used in 
R (Revolution Analytics) to determine differences among the designated recording 
periods in each class of treatments in the bath-applied method and in the pipette-
applied method.  Significant differences were further analyzed using the Friedman-
test-with-post-hoc command for multiple comparisons.  
In order to determine the effect of GSH concentrations (5x10-8, 5x10-7, 5x10-6) on 
the parameters measured, T1 + T2 were added together in the bath-applied method and 
in the pipette-applied method.  The treatment periods for each concentration were 
compared with FANOVAs for each parameter measured.  Significant differences were 
analyzed with post-hoc analysis.  Thus, comparisons were made between (GSH 5x10-
8, GSH 5x10-7, GSH 5x10-6) in the bath-applied method and in the pipette-applied 
method.     
In post-hoc analysis, to determine whether the treatments in the bath-applied 
method were significantly different from those in the pipette-applied method, 
comparisons were made as follows:  For each set of trials in which T1 and T2 were not 
significantly different from each other either in the bath-applied or pipette-applied 
method, T1+T2 were added to create the parameter Tb (bath applied) and Tp (pipette 
applied) which were compared with the Welch two-sample t-tests for SUHPs, MUHPs 
LUHPs, XLUHPs, PBPs, P/PBPs and RPs.  In those cases where T1 and T2 were 
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significantly different from each other in either method, T1 of the bath-applied method 
was compared to T1 of the pipette-applied method and T2 of the bath-applied was 
compared to T2 of the pipette-applied method. SUHPs, MUHPs, LUHPs, XLUHPs 
and PBPs are presented as medians ±	 inter-quartile ranges (m ± i.q.r.) and as means ±	 
standard deviations  (µ ±	 s.d.).  P/PBP are the average number of pulses per 
pacemaker burst and are calculated by taking the total number of pulses in each PBP 
and dividing the total by the number of PBPs in that period.  RPs and P/PBP are 
reported as medians  ±	 inter-quartile ranges (m ±	 i.q.r) and as	 means ±	 standard 
error (µ ±	 s.e.). Values were considered to be significantly different at P< 0.5, with a 
potentially significant trend at 0.05<P<0.1 (Guertin and Kass-Simon, 2015). 
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RESULTS 
I. Effect of GSH Concentration  
a) Bath-applied  
GSH at 5x10-6M (Fig. 4) caused significant increases in SUHPs in treatment 
period (T1) and (T2) relative to BVC control period (C2) (SUHPs: Table 1a, T1>C2*, 
p≤0.0426, T1>C2*, p≤0.0428).  GSH at 5x10-6M caused significant increases in 
MUHPs in treatment period (T1) relative to BVC control period (C2) (MUHPs: Table 
2a, T1>C2*, p≤0.00505).  GSH at 5x10-6M caused significant increases in PBPs and 
P/PBPs in treatment period (T1) relative to BVC control period (C2) and potentially 
significant increases in treatment period (T2) relative to (C2) (PBPs: Table 5a, 
T1>C2*, p≤0.0152, T2>C2^, p≤0.0537; P/PBPs: Table 6a, T1>C2*, p≤0.0151, 
T2>C2^, p≤0.0538).  GSH at 5x10-7M caused significant increases in SUHPs in 
treatment period (T1) relative to BVC control period (C2) (SUHPs: Figure 7, Table 1a, 
T1>C2*, p≤0.00984).  GSH at 5x10-7M caused significant decreases in XLUHPs in 
treatment period (T2) relative to BVC control period (C2) and potentially significant 
decreases in treatment period (T2) relative to treatment period (T1) (XLUHPs, Figure 
8, Table 4a, T2<C2*, p≤0.0428, T2<T1^, p≤0.0612).  GSH at 5x10-8M caused 
potentially significant decreases in LUHPs and RPs in treatment period (T2) relative 
to BVC control period (C2) (LUHPs, Table 3a, T2<C2^, p≤0.0693; RPs, Table 7a, 
T2<C2^, p≤0.0751).  GSH at 5x10-8M caused significant decreases in MUHPs in 
treatment period (T2) relative to treatment period (T1) (MUHPs, Table 2a, T2<T1*, 
p≤0.0266).  GSH at 5x10-8M caused significant increases in PBPs in treatment period 
(T2) relative to BVC control period (C2) (PBPs: Table 5a, T2>C2*, p≤0.0327).            
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There was a significant increase in frequency of SUHPs in GSH 5x10-6 relative 
to GSH 5x10-7 (Figure 9, Table 16a,  p≤0.00195*) and a potentially significant 
increase in SUHPs in GSH 5x10-8 relative GSH 5x10-7 (Figure, 9, Table 16a, 
p≤0.0604^)—suggesting that the higher and lower concentrations of GSH were able to 
induce smaller, neuronal pulses.  There were no significant differences in LUHPs or 
XLUHPs at these concentrations (Figure 10, Table 16a).  There was a significant 
increase in PBPs and P/PBPs in GSH 5x10-8 relative to GSH 5x10-6 (Figure 11, 
Table 16a, PBPs: p≤0.0444*, P/PBPs: p≤0.0184*)—suggesting that the stronger 
concentration of GSH may saturated receptors, decreasing larger muscle pulses 
associated with contraction bursts. There was a significant increase in RPs in GSH 
5x10-6 relative to GSH 5x10-7 (Figure 9, Table 16a, RPs: p≤0.0104*)—suggesting 
that the stronger concentration of GSH induced small, RPs.   
 b) Pipette-Applied  
GSH at 5x10-6M caused significant decreases in XLUHPs in treatment period 
(T2) and (T1) relative to BVC control periods (C1) and (C2) (XLUHPS: Table 4b, 
T1<C1*, p≤0.0323; T2<C1*, p≤0.0323; T1<C2*, p≤0.0171; T2<C2*, p≤0.0169).  
GSH at 5x10-7M caused potentially significant increases in MUHPs in treatment 
period (T1) relative to BVC control period (C2) (MUHPs: Figure 12, Table 2b, 
T1>C2^, p≤0.0741).  GSH at 5x10-8M caused significant decreases in P/PBPs in 
treatment period (T1) relative to BVC control period (C1) (P/PBPs: Table 6b, 
T1<C1*, p≤0.0157).  
There was a significant decrease in LUHPs, XLUHPs, PBPs and P/PBPs in GSH 
5x10-6M relative to GSH 5x10-7M (LUHPs: Figure 13, Table 16b, p≤0.0324*; 
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XLUHPs: Figure 13, Table 16b, p≤0.0140*; PBPs: Figure 14, Table 16b, p≤0.0483*; 
P/PBPs: Figure 14, Table 16b, p≤0.0379*).  There were no significant differences in 
SUHPs, MUHPs or RPs at these concentrations (Figure 15, Table 16b).   
 
II. Effect of GABA on GSH-elicited potentials 
a). Bath-applied  
 GABA at 1x10-6M combined with GSH at 5x10-7M produced no significant 
differences in the rates of any of the six parameters being measured, compared to plain 
BVC control periods (p>0.1) (Figure 7, 8, 16-20, Table 1a-7a).   
b). Pipette-applied 
GABA at 1x10-6M combined with GSH at 5x10-7M caused significant 
increases in LUHPs and potentially significant increases in P/PBPs in treatment period 
(T2) relative to BVC control period (C2) (LUHPs: 21, Table 3b, T2>C2*, p≤0.0440; 
P/PBPs: Figure 22, Table 6b, T2>C2^, p≤0.0569).  GABA at 1x10-6M combined with 
GSH at 5x10-7M caused significant increases in XLUHPs in treatment period (T1) 
relative to BVC control period (C1) (XLUHPs: Figure 23, Table 4b, T1>T1*, 
p≤0.0450).  GABA at 1x10-6M combined with GSH at 5x10-7M caused significant 
increases in RPs in treatment period (T1) relative to BVC control period (C2) (RPs: 
Figure 24, Table 7b, T1>C2*, p≤0.03235).   
Although GABA at 1x10-6M combined with GSH at 5x10-7M produced no 
significant differences in the rates of any of the parameters measured in the bath-
applied method, GABA at 1x10-6M combined with GSH at 5x10-7M increased four of 
the seven parameters measured in the pipette-applied method—LUHPs, XLUHPs, 
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PBPs and RPs (Figure 25) (Table 3b, 4b, 5b, 7b).  The number of pulses produced for 
the parameters MUHPS, LUHPs, XLUHPs, PBPs, P/PBPs and RPs in the pipette-
applied method was also significantly greater relative to the pipette-applied method.    
 
III. Effect of Baclofen on GSH-elicited potentials 
a). Bath-applied  
Baclofen, administered at 1x10-8M in the presence of 5x10-7M GSH, caused a 
potentially significant increase in MUHPs in T2 relative to BVC control period (C2) 
(MUHPs: Figure 16, Table 2a T2>C2^ p≤0.0798).  
b). Pipette-applied 
Baclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused 
significant decreases in SUHPs in treatment period (T2) relative to BVC control 
periods (C1) and (C2) and potentially significant decreases in treatment period (T1) 
relative to BVC control period (C1) (SUHPs: Figure 26, Table 1b, T1<C1^, 
p≤0.06227, T2<C1*, p≤0.00236, T2<C2*, p≤0.00536).  Baclofen, administered at 
1x10-8M in the presence of 5x10-7M GSH caused significant decreases in XLUHPs in 
treatment period (T2) relative to BVC control period (C1) and (C2) and caused 
significant decreases in XLUHPs in treatment period (T1) relative to BVC control 
period (C2) (XLUHPs: Figure 23, Table 4b: T2<C1*, p≤0.0413; T2<C2*, p≤0.0109; 
T1<C2*, p≤0.0414).  Baclofen, administered at 1x10-8M in the presence of 5x10-7M 
GSH caused significant decreases in P/PBPs in treatment period (T1) and (T2) relative 
to BVC control period (C1) (P/PBPs: Figure 22, Table 6b, T1<C1*, p≤0.00827, 
T2<C1*, p≤0.0439).        
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  Baclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused 
significant decreases in SUHPs in the bath-applied method (Table 1a), however, 
baclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused significant 
increases in SUHPs, XLUHPs, and P/PBPs in the pipette-applied method (Figure 27, 
Table 1b, 4b, 6b).  In addition, the pipette-applied method produced significantly more 
SUHPs relative to the bath-applied method (Table 8).   
  
IV. Effect of Phaclofen on GSH-elicited potentials 
a). Bath-applied 
 Phaclofen, administered at 1x10-8M in the presence of 5x10-7M GSH, caused a 
potentially significant decrease in SUHPs in T2 relative to BVC control period (C2) 
(SUHPs: Figure 7, Table 1a, T2<C2^ p≤0.0784).  
b). Pipette-applied 
Phaclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused 
potentially significant increases in LUHPs in treatment period (T2) relative to BVC 
control period (C2) (LUHPs: Figure 21, Table 3b, T2>C2^, p≤0.0734).  Phaclofen, 
administered at 1x10-8M in the presence of 5x10-7M GSH caused significant decreases 
in XLUHPs in (XLUHPs, Figure 23, Table 4b, T2<T1*, p≤0.00821) and potentially 
significant decreases in PBPs in treatment period (T2) relative to treatment period (T1) 
(PBPs: Figure 28, Table 5b, T2<T1^, p≤0.0709).  
Phaclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused 
potentially significant decreases in SUHPs in the bath-applied method (Table 1a).  
Phaclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused increases 
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in LUHPs but decreases in XLUHPs and PBPs in the pipette-applied method (Table 
3b, 4b, 5b).  Phaclofen, inhibits, the inhibition produced by the GABA mechanism.  In 
addition, Phaclofen administered along with GSH 5x10-7M caused significantly 
higher SUHPs, MUHPs and LUHPs in the pipette-applied method relative to the bath-
applied method (Figure 29, Table 8, 9, 10).  In the case where treatment period 1 (T1) 
was different from treatment period 2 (T2) for PBPs, the pipette-applied method 
caused potentially significant increases in PBPs relative to the bath-applied method 
(Table 15c).       
 
V. Effect of Baclofen and Phaclofen on GSH-elicited potentials 
a). Bath-applied 
 Baclofen, at 1x10-8M, added with 1x10-8M Phaclofen and 5x10-7M GSH 
caused a significant decrease in MUHPs and RPs in T2 relative to BVC control period 
(C2) (MUHPs: Figure 16, Table 2a, T2<C2*, p≤0.00379; RPs: Figure 20, Table 7a, 
T2<C2*, p≤0.00969).   
b). Pipette-applied  
Baclofen, at 1x10-8M, added with 1x10-8M Phaclofen and 5x10-7M GSH 
caused significant decreases in SUHPs in treatment period (T2) relative to BVC 
control periods (C1) and (C2) (SUHPs: Figure 26, Table 1b, T2<C1*, p≤0.0106, 
T2<C2*, p≤0.0196).   
Baclofen, at 1x10-8M, added with 1x10-8M Phaclofen and 5x10-7M GSH 
caused decreases in MUHPs and RPs in the bath-applied method (Table 2a, 7a) and 
decreases in SUHPs in the pipette-applied method (Table 1b).  In addition, Baclofen, 
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at 1x10-8M, added with 1x10-8M Phaclofen and 5x10-7M GSH caused significantly 
higher MUHPs, LUHPs, PBPs and P/PBPs in the pipette-applied method relative to 
the bath-applied method (Figure 30, Table 9, 10, 12, 13).     
 
VI. Comparison of Responses in Bath-applied method vs. pipette applied method 
where treatment period 1 (T1) was the same relative to treatment period 2 (T2) 
 
a).  Effect of the bath-applied method vs. pipette-applied method on GSH Dose 
Response 
 GSH at 5x10-6M caused potentially significant increases in SUHPs and 
significantly increased the amount of XLUHPs in the bath-applied treatment (Tb) 
relative to the pipette-applied treatment (Tp) (SUHPS: Table 8, Tb>Tp^, p≤0.0702; 
XLUHPs: Table 11, Tb>Tp*, p≤0.0265).  GSH at 5x10-6M caused significant 
decreases in PBPs and P/PBPs in the bath-applied treatment relative to the pipette-
applied treatment (PBPs: Table 12, Tb<Tp*, p≤0.00649; P/PBPs: Table 13, Tb<Tp*, 
p≤0.00256).  GSH at 5x10-7M caused significant decreases in SUHPs, LUHPs, PBPs, 
P/PBPs and RPs in the (Tb) relative to the (Tp) (SUHPs, Table 8, Tb<Tp*, p≤0.0126; 
LUHPs, Table 10, Tb<Tp*, p≤0.0146; PBPs, Table 12, Tb<Tp*, p≤0.00369; P/PBPs, 
Tb<Tp*, p≤0.005567; RPs, Table 14, Tb<Tp*, p≤0.0254).  GSH at 5x10-8M caused 
potentially significant decreases in PBPs in (Tb) relative to (Tp) (PBPs: Table 12, 
Tb<Tp*, p≤0.0982).   
Thus, increased level of electrical activity in the parameters measured was 
greater in the pipette-applied method relative to the bath-applied method.   
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b).  Effect of the bath-applied method vs. pipette-applied method on GABA-elicited 
GSH-potentials 
 GABA at 1x10-6M combined with GSH at 5x10-7M caused significant 
decreases in XLUHPs, PBPs, P/PBPs and RPs in the treatment bath-applied (Tb) 
relative to the treatment pipette-applied (Tp) (XLUHPs: Table 11, Tb<Tp*, 
p≤0.000182; PBPs: Table 12, Tb<Tp*, p≤0.0000499; P/PBPs: Table 13, Tb<Tp*, 
p≤0.0326; RPs: Table 14, Tb<Tp*, p≤0.00657).   
Thus, the increased level of activity in the parameters measured was greater in 
the pipette-applied method relative to the bath-applied method.  
c).  Effect of the bath-applied method vs. pipette-applied method on Baclofen-elicited 
GSH-potentials 
Baclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused 
significant decreases in SUHPs in the treatment bath-applied (Tb) relative to the 
treatment pipette-applied (Tp) (SUHPs: Table 8, Tb<Tp*, p≤0.00364).  
Small pulses with no observable pattern in behavior may be produced by the 
endoderm located in the hypostome associated with elongation of the mouth during 
feeding.  Baclofen caused significant increases in small pulses (SUHPs) in the pipette-
applied method relative to the bath-applied method where GABA is also found to be 
working, suggesting that there are more GABA B receptors at the apex.  
d). Effect of the bath-applied method vs. pipette applied method on Phaclofen-elicited 
GSH-potentials 
Phaclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused 
significant decreases in SUHPs, MUHPs and LUHPs in the treatment bath-applied 
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(Tb) relative to the treatment pipette-applied (Tp) (SUHPs: Table 8, Tb<Tp*, 
p≤0.00758; MUHPs, Table 9, Tb<Tp*, p≤0.00309; LUHPs: Table 10, Tb<Tp*, 
p≤0.0119).   
Thus, increased level of electrical activity in the parameters measured was 
greater in the pipette-applied method relative to the bath-applied method.  
e). Effect of the bath-applied method vs. pipette-applied method on Baclofen and 
Phaclofen-elicited GSH-potentials 
Baclofen, at 1x10-8M, added with 1x10-8M Phaclofen and 5x10-7M GSH 
caused potentially significant decreases in MUHPs and significant decreases in 
LUHPs, PBPs and P/PBPs in treatment bath-applied (Tb) relative to treatment pipette-
applied (Tp) (MUHPs: Table 9, Tb<Tp^, p≤0.0702; LUHPs: Table 10, Tb<Tp*, 
p≤0.00943; PBPs: Table 12, Tb<Tp*, p≤ 2.60x10-6; P/PBPs: Table 13, Tb<Tp*, 
p≤0.00272).  
Baclofen, coadministered with Phaclofen and GSH caused significantly more 
medium, large, pacemaker bursting pulses and pacemaker per pacemaker bursting 
pulses in the pipette-applied method relative to the bath-applied method.  GSH 
administered alone caused significant increases in medium and larger pulses.  Larger 
pulses may be associated with mouth contractions observed prior to mouth opening, 
after mouth elongation.  
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VII. Comparison of Responses in bath-applied method vs. pipette applied method 
where treatment period 1 (T1) was different relative to treatment period 2 (T2)  
 
a). Effect of XLUHP responses using GSH 5x10-7M in the bath-applied method vs. 
pipette-applied method  
 GSH 5x10-7M produced more XLUHPs in treatment period (T2p) for the 
pipette-applied method than the treatment period (T2b) for the bath-applied method 
(Table 15a, T2p>T2b*, p≤0.0469).   
 XLUHPs may be produced by the ectoderm, associated with mouth 
contractions.  Thus, GSH increasing the amount of contractile activity in pipette-
applied method relative to the bath-applied method as well as in the latter treatment 
period may indicate initial mouth elongation followed by secondary mouth 
contractions associated with hydra’s feeding behavior prior to mouth opening.   
b).  Effect of MUHP responses using GSH 5x10-8M the bath-applied method vs. 
pipette-applied method  
GSH at 5x10-8M produced no significant increases or decreases in MUHPs in 
the treatment period (T1p) for the pipette-applied method relative to the treatment 
period (T1b) for the bath-applied method.  GSH at 5x10-8M produced no significant 
increases or decreases in MUHPs in the treatment period (T2p) for the pipette-applied 
method relative to the treatment period (T2b) for the bath-applied method (Table 15b).     
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c).  Effect of PBP responses using GSH 5x10-7M administered with Phaclofen 1x10-
8M in the bath-applied method vs. pipette-applied method  
GSH 5x10-7M administered with Phaclofen 1x10-8M produced potentially 
more PBPs in the treatment period (T1p) for the pipette-applied method than the 
treatment period (T1b) for the bath-applied method (T1P>T1B, p≤0.0617).  GSH 
5x10-7M administered with Phaclofen 1x10-8M for PBPs is the same in the treatment 
period (T2p) for the pipette-applied method as the treatment period (T2b) for the bath-
applied method (Table 15c).     
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DISCUSSION 
 In determining the electrical correlates associated with mouth opening and 
closing behavior, one must first consider the changing anatomical structure observable 
during this behavior.  Of the many behaviors exhibited by hydra during feeding, one 
of the first is the elongation of the hypostome.  As tentacle writhing is activated, the 
cone-shaped hypostome elongates as the tentacles begin to direct the prey homogenate 
towards the mouth opening.  The mouth rapidly opens and contractile motions of the 
hypostome follow.  It is hypothesized that the smaller pulses (SUHPS, RPs, MUHPs 
and LUHPs) may be involved in the initial opening of the hypostome and the larger 
bursting pulses (XLUHPs, PBPs and P/PBPs) may be involved in the observed 
contraction of the hypostome.    
In studies on Hydra, the question of the role of neurotransmitters in modulating 
the GSH-induced feeding response has been raised.  This study presents 
electrophysiology evidence of the GSH-induced feeding response in Hydra and 
evidence that in Hydra, GABA, acting through an inhibitory mechanism, inhibits 
cessation of the GSH-induced feeding response—prolonging hypostomal activity.  
Although it is not possible to specifically discern where the receptor ligands are 
affecting the pacemaker systems, the above findings support previous studies on 
GABA receptor ligands altering hydra’s pacemaker activity  (Concas et al., 1998; 
Kass-Simon et al, 2003; Kass-Simon and Scappaticci, 2004; Kass-Simon and 
Scappaticci, 2008).  
In order to find out the exact role of GABA in modulating the GSH-induced 
feeding response, we recorded from reduced-tentacle hypostomes.  At the apex of the 
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hypostome, there are sensory cells; distributed perpendicular to the apex of the 
hypostome, there are ganglion cells.  The large putative hypostomal contraction 
pacemaker pulses may be produced by pacemaker neurons associated with the 
proximal nerve ring (Kass-simon, 1972, Hufnagel and Kass-Simon unpublished) and 
the epithelial muscular cells.  The small, uncorrelated hypostomal pulses do not make 
patterns and appear to be neuronal and part of the hypostomal nerve net.  The medium, 
uncorrelated hypostomal pulses may or may not be a subset of the large, uncorrelated 
hypostomal pulses because they do not fall into a bursting pattern.  The rhythmic 
potentials have previously been found to be conducted on the endoderm and are 
associated with the contraction of the circular endodermal epithelial muscle cells 
(Kass-Simon and Passano, 1978). The small, uncorrelated hypostomal pulses binned 
in the present analysis include the frequency of rhythmic potentials.   
We hypothesize that GSH induces the subtentacular pacemaker system located at 
or near the proximal nerve ring due to the increased level of extra-large uncorrelated 
hypostomal pulses (XLUHPs) in the bath-applied method—not observed during the 
pipette-applied method.  Pacemaker activity, at the site of a loosely involved nerve 
ring under the tentacles can be GSH-induced.  GABA, through its inhibitory 
mechanism, may be inhibiting some neuron that was previously inhibiting the GSH 
response.  
  
I. Effect of GSH Concentration  
 In the bath-applied method, GSH increased small-uncorrelated pulses, 
(SUHPs), medium-uncorrelated pulses (MUHPs), pacemaker bursting pulses (PBPs) 
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and pulses per pacemaker bursting pulse (P/PBPs).  In the pipette-applied method 
GSH did not affect SUHPs but increased MUHPs and decreased XLUHPs and 
P/PBPs; this supports previously observed GSH induced cone-formation of the 
hypostome, now hypothesized to be reflected in the increase in medium sized pulses 
(MUHPs) and the concurrent inhibition of body contraction (considered to be 
mediated by XLUHPs and PBPs which are presumed to include neuroeffector 
responses to the activity of the proximal nerve ring and pacemaker system. The 
absence of activity attributed to rhythmic potentials in this finding is supported by 
previous studies in that the contraction burst system (ectodermal pulses) may inhibit 
the RP system (Passano and McCullough, 1963; Taddei-Ferretti and Chillemi, 1987).  
Kass-Simon et al., 1975 showed a morphological basis for the communication 
between the endoderm and the ectoderm through gap junctions, and thus, the 
ectodermal contraction burst system communicates with the endodermal rhythmic 
potential system such that the CB system will contract and inhibit the RP system until 
the contraction is over and an RP results.  It is our hypothesis that the PBP system is a 
subset of the CB system.  That both PBPs and P/PBPs were affected suggests that an 
entire PBP system in the hypostome may exist and has been essentially activated. 
Comparison of responses in bath-applied method vs. pipette-applied method revealed 
that GSH at 5x10-7 caused significantly more pulses in the pipette-applied method 
where the base of the hypostome was blocked, and ligand administration was directly 
at the apex of the mouth.  Whether the mouth opened during recording is unknown.  
Thus, the increased level of electrical activity in the parameters measured and 
compared in the pipette-applied method relative to the bath-applied method support 
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the hypothesis that the receptors for GSH may be located towards the distal portion of 
the mouth near the apex of the hypostome.   
 
II. Effect of GABA on GSH-elicited potentials 
The administration of GABA with GSH yielded no activity in the bath-applied 
method where the mouth of the hypostome was blocked.  However, GSH administered 
with GABA in the pipette-applied method where ligand was in direct contact with the 
mouth opening produced increased larger pulse activity and rhythmic potentials.  The 
prolonged GSH-induced electrical activity by GABA and subsequent increased larger 
bursting pulses suggests that GABA essentially inhibited the cessation of the GSH-
induced pacemaker activity.  Comparison of responses in the parameters measured 
yielded higher activity in the pipette-applied method relative to the bath-applied 
method.  This supports the hypothesis that GABA is acting at the distal portion or 
apex of the hypostome.    
III. Effect of Baclofen on GSH-elicited potentials 
Baclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused 
significant decreases in SUHPs in the bath-applied method. Baclofen, administered at 
1x10-8M in the presence of 5x10-7M GSH where ligand was in direct contact with 
mouth opening caused significant increases in SUHPs, XLUHPs, and P/PBPs in the 
pipette-applied method. This suggests that there are metabotropic GABAB neuronal 
receptors on the hypostomal nerve net, which include neurons of the pacemaker 
systems that mediate cone formation and hypostomal and body contractions.  Baclofen 
caused significant increases in small pulses (SUHPs) in the pipette-applied method 
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relative to the bath-applied method where GABA is also found to be working. These 
small pulses with no observable pattern in behavior may be produced by the endoderm 
located in the hypostome associated with elongation of the mouth during feeding.  
This outcome is supported by recent findings in which the endodermal layer of the 
hypostome was labeled with anti-GABAB receptor antibody (Hufnagel and Kass-
Simon, unpublished).  
 
IV. Effect of Phaclofen on GSH-elicited potentials 
Phaclofen, administered at 1x10-8M in the presence of 5x10-7M GSH caused 
potentially significant decreases in SUHPs in the bath-applied method, supporting the 
idea that neuronal metabotropic GABAB receptors are distributed around the 
hypostome. Phaclofen caused significantly higher small, medium, and large pulses in 
the pipette-applied method relative to the bath-applied method, indicating that GABAB 
receptors at the mouth or the lining of the mouth inhibit mouth closure and that these 
pulses are inhibited by the GABAB antagonist, phaclofen. Thus, phaclofen may block 
the inhibitory mechanism caused by GABA and it’s agonist, baclofen, by decreasing 
the amount of small, medium and large pulses associated with mouth elongation 
during hydra’s feeding behavior. 
V. Effect of Baclofen and Phaclofen on GSH-elicited potentials 
Baclofen, coadministered with phaclofen and GSH caused significantly more 
medium, large, pacemaker bursting pulses and pacemaker per pacemaker bursting 
pulses in the pipette-applied method relative to the bath-applied method.  GSH 
administered alone caused significant increases in medium and larger pulses.  Larger 
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pulses may be associated with mouth contractions observed secondary to mouth 
elongation but prior to mouth opening.  Thus, baclofen together with phaclofen may 
wipe out the inhibitory mechanism of GABA prolonging the cessation of the feeding 
behavior by producing more medium to larger pacemaker bursting pulses in the 
pipette-applied method relative to the bath-applied method where more pacemaker 
cells may be located relative to the newly observed distal nerve ring.   
  Although GABA combined with GSH produced no significant differences in 
the frequency of any of the parameters measured in the bath-applied method, 
coadministration of GSH and GABA alone increased LUHPs, XLUHPs, PBPs and 
RPs in the pipette-applied method (Figure 25).  The results support the behavioral 
observations that GABA inhibits the cessation of the GSH-induced feeding response 
and indicates that GSH and GABA receptors are differentially distributed in the 
hypostome.  It is also possible to conclude that GABA acting through its metabotropic 
receptors is inhibiting the GSH-induced feeding response by altering the underlying 
GSH-induced electrical activity.  This is supported by our findings that the application 
of baclofen and phaclofen on the GSH-induced elicited potentials blocked GABAB 
electrical activity and its presumed contribution to GABA inhibition.  GSH and 
GABA alone caused significant increases in LUHPs, XLUHPs, P/PBPs and RPs; the 
application of baclofen and phaclofen, together with GSH counteracted this effect and 
caused significant decreases in SUHPs, MUHPs and RPs.  Increased levels of 
electrical activity in the parameters measured was greater in the pipette-applied 
method relative to the bath-applied method in all treatments—suggesting that most of 
the GSH receptors may be found in the distal nerve ring closer to the apex of the 
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hypostome relative to the proximal nerve ring located around the base of the 
hypostome (Figure 31).   
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Table 1. The effect of various treatments on the number of small, uncorrelated 
hypostomal pulses in the a) bath-applied method and b) pipette-applied method.  Data 
is reported as means and standard deviation (µ ±	 s.d) and as medians and interquartile 
range (m ±	 i.q.r).  Significance was calculated with FANOVAs.  Asterisks denote a 
significant difference.  Carets denote a potentially significant difference.   
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Table 1 
a) 
 SUHPs 
 
Treatment 
C2 T1 T2  
 
n 
 
Significant 
Differences 
µ ± s.d m ± i.q.r µ ± s.d m ± i.q.r µ ± s.d m ± 
i.q.r 
 
GSH  
5x10-6 
122.86±94
.77 
118 ± 99 294.14 ± 
48.95 
306 ± 
61.5 
204.57 
± 77.49 
225 ± 
126.5 
7 T1>C2*, 
p≤0.0426 
T2>C2*, 
p≤0.0428 
GSH  
5x10-7 
48.25 ± 
37.58 
47 ± 
35.75 
92.88 ± 
53.44 
81.5 ± 
58.25 
79.25 ± 
52.64 
67.5 ± 
86 
8 T1>C2*, 
p≤0.00984 
 
GSH  
5x10-8 
162.88 ± 
80.48 
146.5 ± 
95.5 
173.5 ± 
98.74 
150.5 ± 
158.75 
146.13 
± 80.63 
117.5 ± 
113.75 
8 None 
GSH 5x10-
7 +  GABA 
10-6 
157.63 ± 
88.54 
134 ± 
154.75 
186.13 ± 
125.02 
148 ± 
144.75 
185.38 
± 
136.65 
150.5 ± 
148.5 
8 None 
GSH 5x10-
7 + 
Phaclofen 
10-8 
140.5 ± 
58.23 
133.5 ± 
52.25 
132.25 ± 
56.07 
121.5 ± 
45.5 
85 ± 
21.45 
83.5 ± 
13.5 
8 T2<C2^, 
p≤0.0783 
GSH 5x10-
7 + 
Baclofen 
10-8 
164.18 ± 
98.89 
162 ± 
157 
150 ± 
97.35 
127 ± 
136 
144.55 
± 
102.99 
141 ± 
158.5 
11 None 
GSH 5x10-
7 + 
Baclofen 
10-8 + 
Phaclofen 
10-8 
143.75 ± 
58.93 
121.5 ± 
55.5 
139.75 ± 
37.83 
157.5 ± 
38 
136.25 
± 
102.11 
101.5 ± 
124 
8 None 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
 
Table 1 
b) 
SUHPs 
 
 
Treatment 
C1 C2 T1 T2 
	  
	  
n	  
 
Significant 
Differences µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH  
5x10-6 
205.71	  ±	  108.83	  
156	  ±	  69	   184.86	  ±	  82.21	   136	  ±	  71	  
155.57	  ±	  117.52	   159	  ±	  202.5	  
177.43	  ±	  150.16	  
144	  ±	  262	   7	   None 
GSH  
5x10-7 
205.71	  ±	  108.83	  
156	  ±	  69	   184.86	  ±	  82.21	   136	  ±	  71	   156	  ±	  72.15	   169	  ±	  124.5	   143.57	  ±	  67.01	  
108	  ±	  101.5	   7	   None 
GSH 
5x10-8 
205.71	  ±	  108.83	  
156	  ±	  69	   184.86	  ±	  82.21	   136	  ±	  71	  
130.17	  ±	  120.09	  
71	  ±	  137.25	   71.67	  ±	  51.37	  
51.5	  ±	  61.75	   6	   None 
GSH 5x10-
7 + GABA 
1x10-6 
205.71	  ±	  108.83	  
156	  ±	  69	   184.86	  ±	  82.21	   136	  ±	  71	   225	  ±	  77.04	   235	  ±	  116	   169.14	  ±	  39.87	   178	  ±	  55	   7	   None  
GSH 5x10-
7 + 
Phaclofen 
1x10-8 
205.71	  ±	  108.83	  
156	  ±	  69	   184.86	  ±	  82.21	   136	  ±	  71	   187.71	  ±	  77.75	   200	  ±	  114.5	   174.57	  ±	  65.38	   194	  ±	  69	   7	   None 
GSH 5x10-
7 + 
Baclofen 
1x10-8 
205.71	  ±	  108.83	  
156	  ±	  69	   184.86	  ±	  82.21	   136	  ±	  71	   68.14	  ±	  21.51	   66	  ±	  37	   43.71	  ±	  13.40	   48	  ±	  22	   7	  
T1<C1^, 
p≤0.00623 
T2<C1*, 
p≤0.00237, 
T2<C2*, 
p≤0.00537 
GSH 5x10-
7 + 
Baclofen 
1x10-8 + 
Phaclofen 
1x10-8 
205.71	  ±	  108.83	  
156	  ±	  69	   184.86	  ±	  82.21	   136	  ±	  71	   109.86	  ±	  83.91	   53	  ±	  124.5	   53.43	  ±	  30.56	   47	  ±	  33	   7	  
T2<C1*, 
p≤0.0106 
T2<C2*, 
p≤0.0196 
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Table 2. The effect of various treatments on the number of medium, uncorrelated 
hypostomal pulses in the a) bath-applied method and b) pipette-applied method.  Data 
is reported as means and standard deviation (µ ±	 s.d) and as medians and interquartile 
range (m ±	 i.q.r).  Significance was calculated with FANOVAs.  Asterisks denote a 
significant difference.  Carets denote a potentially significant difference.   
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Table 2 
a) 
MUHPs 
 
 
Treatment 
C2 T1 T2 	  
	  
n	  
 
Significant 
Differences 
µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH 5x10-6 
2.14	  ±	  3.14	   0	  ±	  3.5	   11.71	  ±	  7.57	   13	  ±	  12.5	   3.86	  ±	  3.14	   4	  ±	  5	   7	   T1>C2*, p≤0.00505 
GSH 5x10-7 1.5	  ±	  1	   1	  ±	  1.25	   3.25	  ±	  2.90	   2.5	  ±	  4.75	   6	  ±	  5.59	   5.5	  ±	  6.25	   8	   None 
GSH 5x10-8 6	  ±	  6.26	   6	  ±	  4.75	   7.5	  ±	  6.98	   6	  ±	  8	   4.63	  ±	  6.52	   1	  ±	  6.25	   8	   T2<T1*, p≤0.0266 
GSH 5x10-7 + GABA 
10-6 
8.25	  ±	  9.35	   4.5	  ±	  11	   6.13	  ±	  4.91	   5.5	  ±	  4.75	   4.25	  ±	  7.14	   1	  ±	  2	   8	   None 
GSH 5x10-7 + 
Phaclofen 10-8 
2.13	  ±	  2.09	   1.5	  ±	  2	   1.88	  ±	  2.09	   1.5	  ±	  1.25	   1.13	  ±	  1.36	   0.5	  ±	  2	   8	   None 
GSH 5x10-7 + Baclofen 
10-8 
6.55	  ±	  9.51	   3	  ±	  5.5	   4.91	  ±	  6.27	   3	  ±	  4	   7.18	  ±	  13.97	   2	  ±	  2	   11	   T2>C2^, p≤0.0798 
GSH 5x10-7 + Baclofen 
10-8 + Phaclofen 10-8 
3.88	  ±	  2.09	   3	  ±	  2.75	   4.88	  ±	  7.25	   1	  ±	  6.25	   0.38	  ±	  0.70	   0	  ±	  0.25	   8	   T2<C2*, p≤0.00379 
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Table 2 
b) 
MUHPS 
 
 
Treatment 
C1 C2 T1 T2  
 
n 
 
Significant 
Differences µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH 5x10-6 
6.29	  ±	  3.88	   6	  ±	  5	   3	  ±	  3.66	   2	  ±	  4	   3.71	  ±	  3.49	   2	  ±	  3.5	   7.43	  ±	  6.99	   5	  ±	  11	   7	   None 
GSH 5x10-7 
6.29	  ±	  3.88	   6	  ±	  5	   3	  ±	  3.66	   2	  ±	  4	   11.14	  ±	  5.33	   11	  ±	  7.5	   3.71	  ±	  4.06	   2	  ±	  2.5	   7	   T1>C2^, p≤0.0741 
GSH 5x10-8 
6.29	  ±	  3.88	   6	  ±	  5	   3	  ±	  3.66	   2	  ±	  4	   7	  ±	  7.94	   3	  ±	  6.75	   3	  ±	  2.77	   2	  ±	  3.5	   6	   None 
GSH 5x10-7 + 
GABA10-6 
6.29	  ±	  3.88	   6	  ±	  5	   3	  ±	  3.66	   2	  ±	  4	   6.57	  ±	  7.96	   4	  ±	  5.5	   3.29	  ±	  4.40	   1	  ±	  3.5	   7	   None 
GSH 5x10-7 + 
Phaclofen 10-8 
6.29	  ±	  3.88	   6	  ±	  5	   3	  ±	  3.66	   2	  ±	  4	   6.43	  ±	  3.58	   7	  ±	  4.5	   8.14	  ±	  7.08	   8	  ±	  7	   7	   None 
GSH 5x10-7 + 
Baclofen 10-8 
6.29	  ±	  3.88	   6	  ±	  5	   3	  ±	  3.66	   2	  ±	  4	   4.14	  ±	  4.79	   1	  ±	  5.5	   5.86	  ±	  5.91	   5	  ±	  4.5	   7	   None 
GSH 5x10-7 + 
Baclofen 10-8 + 
Phaclofen 10-8 
6.29	  ±	  3.88	   6	  ±	  5	   3	  ±	  3.66	   2	  ±	  4	   3.14	  ±	  3.31	   2	  ±	  4.0	   5.14	  ±	  5.25	   3	  ±	  4	   7	   None 
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Table 3. The effect of various treatments on the number of large, uncorrelated 
hypostomal pulses in the a) bath-applied method and b) pipette-applied method.  Data 
is reported as means and standard deviation (µ ±	 s.d) and as medians and interquartile 
range (m ±	 i.q.r).  Significance was calculated with FANOVAs.  Asterisks denote a 
significant difference.  Carets denote a potentially significant difference.   
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Table 3  
a) 
LUHPs 
 
 
Treatment 
C2	   T1	   T2	   	  
	  
n	  
 
Significant 
Differences 
µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH 5x10-6 
1.57	  ±	  1.59	   1	  ±	  3	   0.57	  ±	  0.73	   0	  ±	  1	   1.57	  ±	  1.99	   0	  ±	  3	   7	   None 
GSH 5x10-7 
1.25	  ±	  1.20	   1	  ±	  2.25	   0.5	  ±	  0.71	   0	  ±	  1	   1.25	  ±	  1.79	   0	  ±	  2.25	   8	   None 
GSH 5x10-8 
2.13	  ±	  1.83	   1.5	  ±	  3.25	   0.63	  ±	  0.70	   0.5	  ±	  1	   0.38	  ±	  0.48	   0	  ±	  1	   8	   T2<C2^, p≤0.0693 
GSH 5x10-7 + GABA 10-6 
2.25	  ±	  2.49	   1.5	  ±	  4	   3	  ±	  2.83	   2.5	  ±	  3.25	   0.88	  ±	  1.05	   0.5	  ±	  1.25	   8	   None 
GSH 5x10-7 + Phaclofen 
10-8 
1.63	  ±	  3.60	   0	  ±	  0.5	   0.75	  ±	  0.97	   0.5	  ±	  1	   1.13	  ±	  1.36	   0.5	  ±	  2	   8	   None 
GSH 5x10-7 + Baclofen 
10-8 
2.09	  ±	  2.11	   1	  ±	  4	   1.55	  ±	  1.74	   1	  ±	  2.5	   1.64	  ±	  2.62	   1	  ±	  2	   11	   None 
GSH 5x10-7 + Baclofen 
10-8 + Phaclofen 10-8 
0.63	  ±	  0.48	   1	  ±	  1	   0.5	  ±	  0.87	   0	  ±	  0.5	   0.25	  ±	  0.43	   0	  ±	  0.25	   8	   None 
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Table 3 
b) 
LUHPS 
 
 
Treatment 
C1 C2 T1 T2 	  
	  
n	  
 
Significant 
Differences 
µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH 5x10-6 
0.86	  ±	  0.64	   1	  ±	  0.5	   1	  ±	  2.07	   0	  ±	  0.5	   0.57	  ±	  0.73	   0	  ±	  1	   1.14	  ±	  2.80	   0	  ±	  0	   7	   None 
GSH 5x10-7 
0.86	  ±	  0.64	   1	  ±	  0.5	   1	  ±	  2.07	   0	  ±	  0.5	   4.43	  ±	  4.03	   4	  ±	  7	   3.86	  ±	  4.12	   3	  ±	  3.5	   7	   None 
GSH 5x10-8 
0.86	  ±	  0.64	   1	  ±	  0.5	   1	  ±	  2.07	   0	  ±	  0.5	   2.17	  ±	  2.19	   1.5	  ±	  3.25	   0.83	  ±	  0.69	   1	  ±	  0.75	   6	   None 
GSH 5x10-7 + 
GABA 1x10-6 
0.86	  ±	  0.64	   1	  ±	  0.5	   1	  ±	  2.07	   0	  ±	  0.5	   3.29	  ±	  4.86	   1	  ±	  1.5	   5.29	  ±	  7.36	   2	  ±	  4.5	   7	   T2>C2*, p≤0.0440 
GSH 5x10-7 + 
Phaclofen 1x10-8 
0.86	  ±	  0.64	   1	  ±	  0.5	   1	  ±	  2.07	   0	  ±	  0.5	   5.57	  ±	  6.28	   5	  ±	  6.5	   4.71	  ±	  4.40	   4	  ±	  4.5	   7	   T2>C2^, p≤0.0734 
GSH 5x10-7 + 
Baclofen 10-8 
0.86	  ±	  0.64	   1	  ±	  0.5	   1	  ±	  2.07	   0	  ±	  0.5	   1.57	  ±	  1.59	   1	  ±	  1.5	   2.57	  ±	  2.82	   2	  ±	  4	   7	   None 
GSH 5x10-7 + 
Baclofen 10-8 + 
Phaclofen 10-8 
0.86	  ±	  0.64	   1	  ±	  0.5	   1	  ±	  2.07	   0	  ±	  0.5	   4	  ±	  3.82	   5	  ±	  6.5	   5.57	  ±	  6.39	   3	  ±	  8	   7	   None 
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Table 4: The effect of various treatments on the number of extra-large, uncorrelated 
hypostomal pulses in the a) bath-applied method and b) pipette-applied method.  Data 
is reported as means and standard deviation (µ ±	 s.d) and as medians and interquartile 
range (m ±	 i.q.r).  Significance was calculated with FANOVAs.  Asterisks denote a 
significant difference.  Carets denote a potentially significant difference.   
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Table 4  
a) 
XLUHPs 
 
Treatment 
C2 T1 T2 	  
n	  
 
Significant 
Differences 
µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH 5x10-6 
5.43	  ±	  7.29	   1	  ±	  8	   2	  ±	  2.56	   1	  ±	  1.5	   3.43	  ±	  3.89	   1	  ±	  7	   7	   None 
GSH 5x10-7 
3.75	  ±	  2.49	   4	  ±	  3.5	   3.63	  ±	  3.57	   3	  ±	  2.75	   1.75	  ±	  3.56	   0	  ±	  1.25	   8	  
T2<C2*, 
p≤0.0428 
T2<T1^, 
p≤0.0612 
GSH 5x10-8 
10.13	  ±	  7.27	   7.5	  ±	  7.25	   5.25	  ±	  7.14	   1	  ±	  8.75	   5.38	  ±	  6.82	   0.5	  ±	  12	   8	   None 
GSH 5x10-7 +  
GABA 10-6 
6.88	  ±	  4.54	   7.5	  ±	  5.25	   6.63	  ±	  5.17	   6.5	  ±	  9.75	   2.75	  ±	  5.09	   1	  ±	  2	   8	   None 
GSH 5x10-7 +  
Phaclofen 10-8 
12.25	  ±	  7.84	   13	  ±	  10.75	   10.5	  ±	  8.08	   10.5	  ±	  14	   10.38	  ±	  6.56	   10.5	  ±	  10.25	   8	   None 
GSH 5x10-7 +  
Baclofen 10-8 
5.82	  ±	  6.46	   3	  ±	  12.5	   4.55	  ±	  6.01	   0	  ±	  8.5	   3.55	  ±	  4.92	   2	  ±	  4.5	   11	   None 
GSH 5x10-7 + Baclofen 
10-8 + Phaclofen 10-8 
7	  ±	  6.87	   5	  ±	  9	   3	  ±	  3.74	   1.5	  ±	  4	   6	  ±	  5.63	   5.5	  ±	  12	   8	   None 
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Table 4 
b) 
XLUHPS 
 
Treatment 
C1 C2 T1 T2 	  
	  
n	  
 
Significant 
Differences 
µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH 5x10-6 
11.14	  ±	  3.83	   12	  ±	  7	   12.14	  ±	  6.98	   11	  ±	  11	   0.43	  ±	  0.73	   0	  ±	  0.5	   0.29	  ±	  0.45	   0	  ±	  0.5	   7	  
T1<C1*, 
p≤0.0323 
T2<C1*, 
p≤0.0323 
T1<C2*, 
p≤0.0171 
T2<C2*, 
p≤0.0169 
GSH 5x10-7 
11.14	  ±	  3.83	   12	  ±	  7	   12.14	  ±	  6.98	   11	  ±	  11	   12.86	  ±	  13.31	   7	  ±	  16.5	   12.86	  ±	  10.55	   13	  ±	  20	   7	   None 
GSH 5x10-8 
11.14	  ±	  3.83	   12	  ±	  7	   12.14	  ±	  6.98	   11	  ±	  11	   8.67	  ±	  11.23	   4	  ±	  5.75	   7	  ±	  10.13	   3	  ±	  5.75	   6	   None 
GSH 5x10-7 + 
GABA 10-6 
11.14	  ±	  3.83	   12	  ±	  7	   12.14	  ±	  6.98	   11	  ±	  11	   22.71	  ±	  9.91	   23	  ±	  7.5	   15	  ±	  6.63	   16	  ±	  7	   7	   T1>C1*, p≤0.0450 
GSH 5x10-7 + 
Phaclofen 10-8 
11.14	  ±	  3.83	   12	  ±	  7	   12.14	  ±	  6.98	   11	  ±	  11	   19.43	  ±	  10.18	   20	  ±	  11	   7.71	  ±	  7.59	   2	  ±	  13.5	   7	   T2<T1*, p≤0.00821 
GSH 5x10-7 + 
Baclofen 10-8 
11.14	  ±	  3.83	   12	  ±	  7	   12.14	  ±	  6.98	   11	  ±	  11	   3.86	  ±	  6.17	   0	  ±	  5	   1.71	  ±	  3.81	   0	  ±	  0.5	   7	  
T2<C1*, 
p≤0.0413 
T2<C2*, 
p≤0.0109 
T1<C2*, 
p≤0.0414 
GSH 5x10-7 + 
Baclofen 10-8 
+ Phaclofen 
10-8 
11.14	  ±	  3.83	   12	  ±	  7	   12.14	  ±	  6.98	   11	  ±	  11	   8.43	  ±	  7.89	   10	  ±	  14.5	   5	  ±	  6.82	   2	  ±	  7.5	   7	   None 
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Table 5. The effect of various treatments on the number of pacemaker bursting pulses 
in the a) bath-applied method and b) pipette-applied method.  Data is reported as 
means and standard error (µ ±	 s.d) and as medians and interquartile range (m ±	 i.q.r).  
Significance was calculated with FANOVAs.  Asterisks denote a significant 
difference.  Carets denote a potentially significant difference.   
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Table 5 
a) 
PBPs 
 
Treatment 
C2 T1 T2 	  
n	  
 
Significant 
Differences 
µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH 5x10-6 
1.14	  ±	  0.83	   1	  ±	  0	   0	  ±	  0	   0	  ±	  0	   0.29	  ±	  0.70	   0	  ±	  0	   7	  
T1>C2*, 
p≤0.0152 
T2>C2^, 
p≤0.0537 
GSH 5x10-7 
0.63	  ±	  0.48	   1	  ±	  1	   0.13	  ±	  0.33	   0	  ±	  0	   0.63	  ±	  0.48	   1	  ±	  1	   8	   None 
GSH 5x10-8 
1.63	  ±	  0.99	   1.5	  ±	  1.25	   0.75	  ±	  0.83	   0.5	  ±	  1.25	   0.63	  ±	  0.70	   0.5	  ±	  1	   8	   T2>C2*, p≤0.0327 
GSH 5x10-7 + GABA 10-
6 
0.63	  ±	  0.48	   1	  ±	  1	   0.63	  ±	  0.48	   1	  ±	  1	   0.25	  ±	  0.43	   0	  ±	  0.25	   8	   None 
GSH 5x10-7 + Phaclofen 
10-8 
1.25	  ±	  0.66	   1	  ±	  1	   0.88	  ±	  0.60	   1	  ±	  0.25	   1	  ±	  0.71	   1	  ±	  0.5	   8	   None 
GSH 5x10-7 + Baclofen 
10-8 
1.09	  ±	  0.83	   1	  ±	  1.5	   1	  ±	  1.22	   1	  ±	  1.5	   0.64	  ±	  0.92	   0	  ±	  1	   11	   None 
GSH 5x10-7 + Baclofen 
10-8 + Phaclofen10-8 
0.63	  ±	  0.70	   0.5	  ±	  1	   0.25	  ±	  0.43	   0	  ±	  0.25	   0.5	  ±	  0.5	   0.5	  ±	  1	   8	   None 
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Table 5 
b) 
PBPS 
 
Treatment 
C1 C2 T1 T2 	  
n	  
 
Significant 
Differences 
µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	   µ	  ±	  s.d	   m	  ±	  i.q.r	  
GSH 5x10-6 
1.43	  ±	  0.49	   1	  ±	  1	   1.43	  ±	  0.73	   2	  ±	  1	   1.14	  ±	  1.12	   1	  ±	  2	   1.14	  ±	  0.99	   2	  ±	  2	   7	   None 
GSH 5x10-7 
1.43	  ±	  0.49	   1	  ±	  1	   1.43	  ±	  0.73	   2	  ±	  1	   2.14	  ±	  0.64	   2	  ±	  0.5	   1.29	  ±	  1.03	   1	  ±	  1.5	   7	   None 
GSH 5x10-8 
1.43	  ±	  0.49	   1	  ±	  1	   1.43	  ±	  0.73	   2	  ±	  1	   2	  ±	  1.41	   2	  ±	  2	   1.17	  ±	  0.69	   1	  ±	  0.75	   6	   None 
GSH 5x10-7 + 
GABA 10-6 
1.43	  ±	  0.49	   1	  ±	  1	   1.43	  ±	  0.73	   2	  ±	  1	   2.43	  ±	  0.90	   2	  ±	  1	   1.57	  ±	  0.73	   1	  ±	  1	   7	   None 
GSH 5x10-7 + 
Phaclofen 10-8 
1.43	  ±	  0.49	   1	  ±	  1	   1.43	  ±	  0.73	   2	  ±	  1	   2.14	  ±	  1.25	   2	  ±	  1.5	   0.86	  ±	  0.83	   1	  ±	  1.5	   7	   T2<T1^, p≤0.0855 
GSH 5x10-7 + 
Baclofen 10-8 
1.43	  ±	  0.49	   1	  ±	  1	   1.43	  ±	  0.73	   2	  ±	  1	   1.29	  ±	  1.48	   0	  ±	  3	   1.57	  ±	  1.18	   2	  ±	  2	   7	   None 
GSH 5x10-7 + 
Baclofen 10-8 + 
Phaclofen 10-8 
1.43	  ±	  0.49	   1	  ±	  1	   1.43	  ±	  0.73	   2	  ±	  1	   2	  ±	  0.53	   2	  ±	  0	   1.43	  ±	  0.49	   1	  ±	  1	   7	   None 
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Table 6. The effect of various treatments on the number of pulses per pacemaker 
bursting pulse in the a) bath-applied method and b) pipette-applied method.  Data is 
reported as means and standard error (µ ±	 s.e) and as medians and interquartile range 
(m ±	 i.q.r).  Significance was calculated with FANOVAs.  Asterisks denote a 
significant difference.  Carets denote a potentially significant difference.   
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Table 6 
a) 
P/PBPs 
 
Treatment 
C2 T1 T2 	  
n	  
 
Significant 
Differences µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	  
GSH 5x10-6 9.29	  ±	  1.93	   9	  ±	  4	   0	  ±	  0	   0	  ±	  0	   1.36	  ±	  1.26	   0	  ±	  0	   7	   T2>C2^, p≤0.0538 
T1<C2*, 
p≤0.0151 
GSH 5x10-7 4.25	  ±	  1.31	   4.5	  ±	  7.25	   1.5	  ±	  1.40	   0	  ±	  0	   6.63	  ±	  2.40	   6	  ±	  9	   8	   None 
GSH 5x10-8 9.28	  ±	  1.41	   9.8	  ±	  3.55	   5.56	  ±	  2.13	   3.5	  ±	  10.13	   5.13	  ±	  1.92	   3	  ±	  11.25	   8	   None 
GSH 5x10-7 + 
GABA 10-6 
7.75	  ±	  2.31	   9.5	  ±	  11.75	   9.88	  ±	  3.11	   11	  ±	  15.25	   3.63	  ±	  2.36	   0	  ±	  2.5	   8	   None 
GSH 5x10-7 + 
Phaclofen 10-8 
10.13	  ±	  2.11	   9.5	  ±	  8.25	   9.56	  ±	  2.06	   2	  ±	  5.25	   9.63	  ±	  2.30	   11.25	  ±	  7.13	   8	   None 
GSH 5x10-7 + 
Baclofen 10-8 
8.55	  ±	  1.89	   9.5	  ±	  11	   4.93	  ±	  1.46	   7	  ±	  8.25	   4.82	  ±	  1.75	   0	  ±	  11	   11	   None 
GSH 5x10-7 + 
Baclofen 10-8 
+ Phaclofen 
10-8 
3.75	  ±	  1.33	   3.5	  ±	  7.25	   2.13	  ±	  1.37	   0	  ±	  1.5	   6	  ±	  2.19	   4.5	  ±	  12	   8	   None 
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Table 6  
b) 
P/PBPS 
 
Treatment 
C1 C2 T1 T2 	  
n	  
 
Significant 
Differences 
µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	  
GSH 5x10-6 
9.29	  ±	  1.52	   8.5	  ±	  5.75	   7.29	  ±	  1.38	   8	  ±	  4.25	   3.14	  ±	  1.20	   3.5	  ±	  4.75	   7.55	  ±	  1.53	   8.5	  ±	  5.09	   7	   None 
GSH 5x10-7 
9.29	  ±	  1.52	   8.5	  ±	  5.75	   7.29	  ±	  1.38	   8	  ±	  4.25	   12.76	  ±	  1.57	   11	  ±	  4.92	   12.02	  ±	  3.22	   13	  ±	  11.92	   7	   None 
GSH 5x10-8 
9.29	  ±	  1.52	   8.5	  ±	  5.75	   7.29	  ±	  1.38	   8	  ±	  4.25	   6.21	  ±	  1.43	   6.17	  ±	  1.15	   6.83	  ±	  1.61	   7	  ±	  4.63	   6	   T1<C1*, p≤0.0157 
GSH 5x10-7 + 
GABA 10-6 
9.29	  ±	  1.52	   8.5	  ±	  5.75	   7.29	  ±	  1.38	   8	  ±	  4.25	   11.91	  ±	  1.64	   11	  ±	  6	   16.14	  ±	  1.80	   16	  ±	  3.75	   7	   T2>C2^, p≤0.0569 
GSH 5x10-7 + 
Phaclofen 10-8 
9.29	  ±	  1.52	   8.5	  ±	  5.75	   7.29	  ±	  1.38	   8	  ±	  4.25	   12.56	  ±	  4.50	   7.5	  ±	  9.05	   9.07	  ±	  3.38	   9.5	  ±	  16	   7	   None 
GSH 5x10-7 + 
Baclofen 10-8 
9.29	  ±	  1.52	   8.5	  ±	  5.75	   7.29	  ±	  1.38	   8	  ±	  4.25	   2.76	  ±	  1.22	   0	  ±	  5.83	   6.40	  ±	  1.68	   7.33	  ±	  6.75	   7	  
T1<C1*, 
p≤0.00827 
T2<C1*, 
p≤0.0439 
GSH 5x10-7 + 
Baclofen 10-8 + 
Phaclofen 10-8 
9.29	  ±	  1.52	   8.5	  ±	  5.75	   7.29	  ±	  1.38	   8	  ±	  4.25	   14.12	  ±	  3.45	   9.5	  ±	  9.59	   12	  ±	  1.52	   10.5	  ±	  6.75	   7	   None 
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Table 7. The effect of various treatments on the RP system in the a) bath-applied 
method and b) pipette-applied method.  Data is reported as means and standard error 
(µ ±	 s.e) and as medians and interquartile range (m ±	 i.q.r).  Significance was 
calculated with FANOVAs.  Asterisks denote a significant difference.  Carets denote a 
potentially significant difference.   
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Table 7 
a) 
RPs 
 
Treatment 
C2 T1 T2 	  
n	  
 
Significant 
Differences 
µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	  
GSH 5x10-6 
2.14	  ±	  1.08	   0	  ±	  4	   5.71	  ±	  2.26	   4	  ±	  7.5	   6.29	  ±	  2.01	   7	  ±	  6	   7	   None 
GSH 5x10-7 
0.75	  ±	  0.46	   0	  ±	  1	   1.13	  ±	  0.57	   0.5	  ±	  1.25	   0.63	  ±	  0.35	   0	  ±	  1	   8	   None 
GSH 5x10-8 
6.25	  ±	  2.09	   5	  ±	  11.5	   1.63	  ±	  0.86	   1	  ±	  0.25	   1	  ±	  0.40	   2	  ±	  0	   8	   T2<C2^, p≤0.0751 
GSH 5x10-7 + GABA 10-
6 
2.63	  ±	  0.68	   2.5	  ±	  3.25	   2.5	  ±	  0.83	   1.5	  ±	  3.75	   2.13	  ±	  0.48	   2	  ±	  2.25	   8	   None 
GSH 5x10-7 + Phaclofen 
10-8 
7.63	  ±	  2.79	   5.5	  ±	  6.5	   5.25	  ±	  2.32	   2	  ±	  5.25	   3.38	  ±	  1.30	   2	  ±	  3.75	   8	   None 
GSH 5x10-7 + Baclofen 
10-8 
8.73	  ±	  3.54	   3	  ±	  8	   4.27	  ±	  1.63	   2	  ±	  6.5	   3.82	  ±	  1.52	   3	  ±	  4.5	   11	   None 
GSH 5x10-7 + Baclofen 
10-8 + Phaclofen 10-8 
8.75	  ±	  1.48	   7.5	  ±	  6.75	   5.88	  ±	  1.92	   4.5	  ±	  4.5	   3.13	  ±	  1.29	   2	  ±	  3.25	   8	   T2<C2*, p≤0.00969 
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Table 7  
b) 
RPS 
 
 
Treatment 
C1 C2 T1 T2  
n 
 
Significant 
Differences 
µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	   µ	  ±	  s.e	   m	  ±	  i.q.r	  
GSH 5x10-6 3.86	  ±	  1.30	   3	  ±	  5	   2.43	  ±	  1.24	   2	  ±	  2.5	   7	  ±	  2.71	   6	  ±	  6	   7	  ±	  2.36	   6	  ±	  4	   7 None 
GSH 5x10-7 3.86	  ±	  1.30	   3	  ±	  5	   2.43	  ±	  1.24	   2	  ±	  2.5	   10.43	  ±	  5.22	   3	  ±	  13.5	   11.57	  ±	  5.54	   4	  ±	  16	   7 None 
GSH 5x10-8 3.86	  ±	  1.30	   3	  ±	  5	   2.43	  ±	  1.24	   2	  ±	  2.5	   2	  ±	  0.53	   1	  ±	  2.25	   1.83	  ±	  0.46	   1	  ±	  1.5	   6 None 
GSH 5x10-7 + 
GABA 10-6 
3.86	  ±	  1.30	   3	  ±	  5	   2.43	  ±	  1.24	   2	  ±	  2.5	   7.43	  ±	  1.63	   9	  ±	  8	   5	  ±	  1.29	   3	  ±	  3.5	   7 T1>C2*, p≤0.0324 
GSH 5x10-7 + 
Phaclofen 10-8 
3.86	  ±	  1.30	   3	  ±	  5	   2.43	  ±	  1.24	   2	  ±	  2.5	   3.86	  ±	  1.06	   3	  ±	  3.5	   2.71	  ±	  1.52	   1	  ±	  3	   7 None 
GSH 5x10-7 + 
Baclofen 10-8 
3.86	  ±	  1.30	   3	  ±	  5	   2.43	  ±	  1.24	   2	  ±	  2.5	   4.29	  ±	  0.45	   3	  ±	  4	   3.29	  ±	  1.17	   2	  ±	  4.5	   7 None 
GSH 5x10-7 + 
Baclofen 10-8 + 
Phaclofen 10-8 
3.86	  ±	  1.30	   3	  ±	  5	   2.43	  ±	  1.24	   2	  ±	  2.5	   3.29	  ±	  1.34	   3	  ±	  5.5	   3.29	  	  ±	  1.04	   2	  ±	  5	   7 None 
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Table 8: The comparison of SUHP responses in bath-applied method vs. pipette 
applied method where treatment period 1 (T1) was the same as treatment period 2 
(T2).  Data is reported as means and standard deviation (µ ±	 s.d) and as medians and 
interquartile range (m ±	 i.q.r).  Significance was calculated with Welch two-sample t-
tests.  Asterisks denote a significant difference.  Carets denote a potentially significant 
difference.   
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Table 8 
SUHPs 
 
Treatment 
TB TP Significant 
Differences µ + s.d m + i.q.r µ + s.d m + i.q.r 
GSH 5x10-6 249.36 ± 
78.78 
259 ± 
96.75 
166.5± 
135.27 
151.5 ± 
222.75 
TB>TP^ 
p≤0.0702 
GSH 5x10-7 83.57 ± 
54.63 
77 ± 80 149.79 ± 
69.91 
141.5 ± 
130 
TB<TP* 
p≤0.0126 
GSH 5x10-8 156.58 ± 
97.28 
112.5 ± 
165.5 
100.92 ± 
96.88 
63 ± 
85.75 
None 
GSH 5x10-7 + 
GABA 10-6 
194.86 ± 
136.87 
155 ± 
179.75 
197.07 ± 
67.40 
184.5 ± 
88.75 
None 
GSH 5x10-7 + 
Phaclofen 10-8 
109.57± 
50.93 
89.5 ±  
46.25 
181.14 ± 
72.13 
194.5 ± 
74.5 
TB<TP* 
p≤0.00758 
GSH 5x10-7 
+Baclofen 10-8 
165.29 ± 
111.01 
199 ± 
186.5 
55.93 ± 
21.69 
53 ± 
27.25 
TB<TP* 
p≤0.00364 
GSH 5x10-7 
+Phaclofen 10-8 + 
Baclofen 10-8 
128 
±75.60 
130 ± 
81.25 
81.64 ± 
72.84 
50 ± 
47.75 
None 
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Table 9: The comparison of MUHP responses in bath-applied method vs. pipette 
applied method where treatment period 1 (T1) was the same as treatment period 2 
(T2). Data is reported as means and standard deviation (µ ±	 s.d) and as medians and 
interquartile range (m ±	 i.q.r).  Significance was calculated with Welch two-sample t-
tests.  Asterisks denote a significant difference.  Carets denote a potentially significant 
difference.  
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Table 9 
MUHPS 
 
Treatment 
TB TP Significant 
Differences µ + s.d m + i.q.r µ + s.d m + i.q.r 
GSH 5x10-6 7.79  ± 
7.00 
6 ± 10.75 5.57 ± 
5.82 
3 ±7 None 
GSH 5x10- 4.79 ± 
4.79 
4 ± 5.5 7.43 ± 
6.02 
6.5 ± 
10.5 
None 
GSH 5x10-7 + 
GABA 10-6 
4.86 ± 
6.56 
1.5 ± 
4.75 
4.93 ± 
6.64 
2 ± 5 None 
GSH 5x10-7 + 
Phaclofen 10-8 
1.5 ± 1.92 1 ± 2 7.29 ± 
5.67 
7.5 ± 6.5 TB<TP*, 
p≤0.00309 
GSH 5x10-7 
+Baclofen 10-8 
7.5 ± 
12.70 
3 ± 4 5 ± 5.45 3 ± 6.25 None 
GSH 5x10-7 
+Phaclofen 10-8 + 
Baclofen 10-8 
1.36 ± 
2.74 
0 ± 1 4.14 ± 
4.50 
2.5 ± 4.5 TB<TP^, 
p≤0.0702 
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Table 10: The comparison of LUHP responses in bath-applied method vs. pipette 
applied method where treatment period 1 (T1) was the same as treatment period 2 
(T2).  Data is reported as means and standard deviation (µ ±	 s.d) and as medians and 
interquartile range (m ±	 i.q.r).  Significance was calculated with Welch two-sample t-
tests.  Asterisks denote a significant difference.  Carets denote a potentially significant 
difference.   
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Table 10 
LUHPS 
 
Treatment 
TB TP Significant 
Differences µ + s.d m + i.q.r µ + s.d m + iqr 
GSH 5x10-6 1.07 ± 
1.58 
0 ± 1.75 0.86 ± 
2.07 
0 ± 0.75 None 
GSH 5x10-7 0.86 ± 
1.46 
0 ± 1 4.14 ± 
4.09 
3.5 ± 
6.25 
TB<TP*, 
p≤0.0146 
GSH 5x10-8 0.58 ± 
0.64 
0.5 ± 1 1.5 ± 1.76 1 ± 2 None 
GSH 5x10-7 + 
GABA 10-6 
2.21 ± 
2.43 
1.5 ± 
2.75 
4.29 ± 
6.32 
1.5 ± 
1.75 
None 
GSH 5x10-7 + 
Phaclofen 10-8 
0.71 ± 
0.96 
0 ± 1 5.14 ± 
5.44 
4.5 ± 5.5 TB<TP*, 
p≤0.0119 
GSH 5x10-7 
+Baclofen 10-8 
1.71 ± 
2.37 
1 ± 2 2.07 ± 
2.34 
1.5 ± 
2.75 
None 
GSH 5x10-7 
+Phaclofen 10-8 + 
Baclofen 10-8 
0.29 ± 
0.59 
0 ± 0 4.79 ± 
5.32 
4 ± 7.25 TB<TP*, 
p≤0.00943 
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Table 11: The comparison of XLUHP responses in bath-applied method vs. pipette 
applied method where treatment period 1 (T1) was the same as treatment period 2 
(T2).  Data is reported as means and standard deviation (µ ±	 s.d) and as medians and 
interquartile range (m ±	 i.q.r).  Significance was calculated with Welch two-sample t-
tests.  Asterisks denote a significant difference.  Carets denote a potentially significant 
difference.   
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Table 11 
XLUHPS 
 
Treatment 
TB TP Significant 
Differences µ ± s.d m ± i.q.r µ ± s.d m ± i.q.r 
GSH 5x10-6 2.71 ± 
3.37 
1 ± 4.25 0.36 ± 
0.61 
0 ± 0.75 TB>TP*, 
p≤0.0265 
GSH 5x10-8 6 ± 7.51 0.5 ± 12 7.83 ± 
10.73 
3.5 ± 6 None 
GSH 5x10-7 + 
GABA 1x10-6 
5.29 ± 
5.61 
2 ± 8.75 18.86 ± 
9.27 
19 ± 7.75 TB<TP*, 
p≤1.82e-4 
GSH 5x10-7 + 
Phaclofen 10-8 
10.57 ± 
7.46 
10.5 ± 
10.75 
13.57 ± 
10.72 
15 ± 17.5 None 
GSH 5x10-7 
+Baclofen 10-8 
3.86 ± 
5.41 
1 ± 5.5 2.79 ± 
5.24 
0 ± 1 None 
GSH 5x10-7 
+Phaclofen 10-8 + 
Baclofen 10-8 
5.07 ± 
5.11 
2.5 ± 
10.5 
6.71 ± 
7.57 
2 ± 12.75 None 
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Table 12: The comparison of PBP responses in bath-applied method vs. pipette 
applied method where treatment period 1 (T1) was the same as treatment period 2 
(T2).  Data is reported as means and standard deviation (µ ±	 s.d) and as medians and 
interquartile range (m ±	 i.q.r).  Significance was calculated with Welch two-sample t-
tests.  Asterisks denote a significant difference.  Carets denote a potentially significant 
difference.   
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Table 12 
PBPS 
 
Treatment 
TB TP Significant 
Differences µ + s.d m + i.q.r µ + s.d m + i.q.r 
GSH 5x10-6 0.14 ± 
0.52 
0 ± 0 1.14 ± 
1.06 
1.5 ± 2 TB<TP*, 
p≤0.00649 
GSH 5x10-7 0.43 ± 
0.50 
0 ± 1 1.71 ± 
0.96 
2 ± 1 TB<TP*, 
p≤3.69e-4 
GSH 5x10-8 0.83 ± 
0.80 
1 ± 1.25 1.58 ± 
1.19 
1 ± 1.25 TB<TP^, 
p≤0.0982 
GSH 5x10-7 + 
GABA 10-6 
0.5 ± 0.5 0.5 ± 1 2 ± 0.93 2 ± 1.75 TB<TP*, 
p≤4.99e-5 
GSH 5x10-7 
+Baclofen 10-8 
0.86 ± 
1.25 
0 ± 1 1.43 ± 
1.35 
1.5 ± 3 None 
GSH 5x10-7 
+Phaclofen 10-8 + 
Baclofen 10-8 
0.43 ± 
0.50 
0 ± 1 1.71 ± 
0.59 
2 ± 1 TB<TP*, 
p≤2.60e-6 
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Table 13: The comparison of P/PBP responses in bath-applied method vs. pipette 
applied method where treatment period 1 (T1) was the same as treatment period 2 
(T2).  Data is reported as means and standard error (µ ±	 s.e) and as medians and 
interquartile range (m ±	 i.q.r).  Significance was calculated with Welch two-sample t-
tests.  Asterisks denote a significant difference.  Carets denote a potentially significant 
difference.   
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Table 13  
P/PBPS 
Treatment TB TP Significant 
Differences µ + s.e m + i.q.r µ + s.e m + i.q.r 
GSH 5x10-6 0.68 ± 
0.65 
0 ± 0 5.35 ± 
1.14 
5 ± 8 TB<TP*, 
p≤0.00256 
GSH 5x10-7 4.64 ± 
1.70 
0 ± 7.5 12.40 ± 
1.80 
11.84 ± 
7.58 
TB<TP*, 
p≤0.005567 
GSH 5x10-8 6.13 ± 
1.65 
6.5 ± 
11.25 
6.52 ± 
1.16 
6.17 ± 
3.44 
None 
GSH 5x10-7 + 
GABA 10-6 
7.71 ± 
2.29 
5 ± 14.25 14.02 ± 
1.34 
14.34 ± 
6.0 
TB<TP*, 
p≤0.0326 
GSH 5x10-7 + 
Phaclofen 10-8 
8.82 ± 
1.66 
11 ± 
10.13 
10.82 ± 
2.85 
7.63 ± 
16.92 
None 
GSH 5x10-7 
+Baclofen 10-8 
3.84 ± 
1.31 
0 ± 7 4.58 ± 
1.15 
5.83 ± 
7.59 
None 
GSH 5x10-7 
+Phaclofen 10-8 + 
Baclofen 10-8 
4.64 ± 
1.51 
0 ± 10.5 13.06 ± 
1.91 
10 ± 7.75 TB<TP*, 
p≤0.00272 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 69 
 
Table 14: The comparison of RP responses in bath-applied method vs. pipette applied 
method where treatment period 1 (T1) was the same as treatment period 2 (T2).  Data 
is reported as means and standard error (µ ±	 s.e) and as medians and interquartile 
range (m ±	 i.q.r).  Significance was calculated with Welch two-sample t-tests.  
Asterisks denote a significant difference.  Carets denote a potentially significant 
difference.   
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Table 14  
RPs 
Treatment TB TP Significant 
Differences µ + s.e m + i.q.r µ + s.e m + i.q.r 
GSH 5x10-6 6 ± 1.51 4.5 ± 6 7 ± 1.80 6 ± 5.5 None 
GSH 5x10-7 1 ± 0.38 0.5 ± 1 11 ± 3.81 3.5 ± 
17.75 
TB<TP*, 
p≤0.0254 
GSH 5x10-8 1.67 ± 
0.60 
1 ± 1.25 1.92 ± 
0.38 
1 ± 2.25 None 
GSH 5x10-7 + 
GABA 10-6 
2.36 ± 
0.55 
1.5 ± 3 6.21 ± 
1.09 
4.5 ± 
6.75 
TB<TP*, 
p≤0.00657 
GSH 5x10-7 + 
Phaclofen 10-8 
4.79 ± 
1.50 
2 ± 6.5 3.29 ± 
0.94 
2 ± 4.5 None 
GSH 5x10-7 
+Baclofen 10-8 
2.36 ± 
0.95 
1 ± 2.75 3.79 ± 
0.85 
2.5 ± 
5.75 
None 
GSH 5x10-7 
+Phaclofen 10-8 + 
Baclofen 10-8 
4.93 ± 
1.34 
4 ± 4.5 3.29 ± 
0.85 
2.5 ± 6 None 
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Table 15: The comparison of responses in bath-applied method vs. pipette applied 
method where treatment period 1 (T1) was different from treatment period 2 (T2). 
Data is reported as means and standard deviation (µ ±	 s.d) and as medians and 
interquartile range (m ±	 i.q.r).  Significance was calculated with Welch two-sample t-
tests.  Asterisks denote a significant difference.  Carets denote a potentially significant 
difference. a) GSH 5x10-7M, XLUHPs b) GSH 5x10-8M, MUHPs c) GSH 5x10-7M + 
Phaclofen 10-8M:  PBPs.  
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Table 15 
 
a) 
GSH 5x10-7, XLUHPS 
 T1B T1P Significant 
Differences 
µ ± s.d 3.71 ± 3.81 12.86 ± 
13.31 
 
None 
m ± i.q.r 3 ± 3.5 7 ± 16.5 
 T2B T2P  
µ ± s.d 2 ± 3.74 12.86 ± 
10.55 
T2B<T2P*, 
p≤0.0469 
m ± i.q.r 0 ± 1.5 13 ± 20 
 
 
b)  
GSH 5x10-8, MUHPS 
 T1B T1P Significant 
Differences 
µ ± s.d 9 ± 7.46 7 ± 7.94 None 
m ± i.q.r 8.5 ± 8.5 3 ± 6.75 
 T2B T2P Significant 
Differences 
µ ± s.d 6 ±7 3 ± 2.77 None 
m ± i.q.r 2.5 ± 10.50 2 ± 3.5 
 
 
 
c)  
GSH 5x10-7 + Phaclofen 10-8, PBPs 
 T1B T1P Significant 
Differences 
µ ± s.d 0.86 ± 0.64 2.14 ± 1.25 T1P>T1B^, 
p≤0.0617 m ± i.q.r 1 ± 0.5 2 ± 1.5 
 T2B T2P  
µ ± s.d 1 ± 0.76 0.86 ± 0.83 None m	  ±	  i.q.r	   1	  ±	  1.0	   1	  ±	  1.5	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Table 16: The comparison of the dose response of GSH 5x10-8, GSH 5x10-7, GSH 
5x10-6 in the a) bath-applied method and b) pipette-applied method.  Data is reported 
as means and standard deviation (µ ±	 s.d) for SUHPs, MUHPs, LUHPs, XLUHPs, 
PBPs and as means and standard error  (µ ±	 s.e) for P/PBPs and RPs.  Asterisks 
denote a significant difference.  Carets denote a potentially significant difference.    
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Table 16: 
a) 
GSH: Bath-Applied 
 5x10-8 5x10-7 5x10-6 Significant Differences 
SUHPs 165.29	  ±94.00	   84.07	  ±	  55.15	   249.36	  ±	  78.78	   5x10-7 < 5x10-6, p≤0.00195*,  5x10-7 < 5x10-8,p≤0.0604^ 
MUHPs 6.86	  ±	  7.03	   4.79	  ±	  4.78	   7.79	  ±	  7.00	   None 
LUHPs 0.57	  ±	  0.62	   0.86	  ±	  1.46	   1.07	  ±	  1.33	   None 
XLUHPs 6	  ±	  7.20	   2.93	  ±	  3.86	   3.71	  ±	  5.72	   None 
PBPs 0.78	  ±	  0.77	   0.43	  ±	  0.49	   0.14	  ±	  0.52	   5x10-6 < 5x10-8 p≤0.00444* 
P/PBPs 6.11	  ±	  1.44	   4.64	  ±	  1.59	   0.68	  ±	  0.66	   5x10-6 < 5x10-8 p≤0.0184* 
RPs 1.5	  ±	  0.50	   0.79	  ±	  0.33	   6	  ±	  1.51	   5x10-6 > 5x10-7 p≤0.0104* 
b) 
GSH: Pipette-Applied 
 5x10-­‐8	   5x10-­‐7	   5x10-­‐6	   Significant Differences 
SUHPs 165.29	  ±	  94.00	   149.79	  ±	  69.91	   166.50	  ±	  135.27	   None 
MUHPs 6.89	  ±	  7.03	   7.43	  ±	  6.02	   5.57	  ±	  5.82	   None 
LUHPs 1.5	  ±	  1.76	   4.42	  ±	  4.23	   1	  ±	  2.20	   5x10-6 < 5x10-7, 
p≤0.032* 
XLUHP
s 
7.83	  ±	  10.73	   12.33	  ±	  12.09	   0.42	  ±	  0.64	   5x10-6 < 5x10-7, p≤0.0140* 
PBPs 1.58	  ±	  1.19	   1.92	  ±	  0.86	   1	  ±	  1.08	   5x10-6 < 5x10-7, 
p≤0.0483* 
P/PBPs 6.52	  ±	  1.16	   12.46	  ±	  1.43	   4.53	  ±	  1.07	   5x10-6 < 5x10-7, p≤0.0379* 
RPs 1.5	  ±	  0.50	   11	  ±	  3.81	   7	  ±	  1.80	   None 
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Figure 1.  Schematic diagram of an ablated hypostome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 
 
 
Figure 1.  
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Figure 2.  A side view of an ablated hypostome preparation after 24-hr regeneration.  
Tentacle stubs are labeled TS.  The hypostome (mouth) is labeled M. 
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Figure 2.  
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Figure 3. Schematic diagram of bath-applied method electrode placement.  
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Figure 3.  
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Figure 4.  Sample recording from the bath-applied method with GSH 5x10-6 M. a) 
control period (C2); b) treatment period (T1); c) treatment period (T2).  Samples were 
taken from comparable times after the addition of the test substance in each treatment 
period, and control period C2. Diamonds (SUHPs), squares (MUHPs) and stars 
(LUHPs).   
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Figure 4.  
a. 
 
b. 
 
c. 
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Figure 5. Schematic diagram of pipette-applied electrode placement.  
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Figure 5.   
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Figure 6. Sample recording from the pipette-applied method with GSH 5x10-6M.  a) 
treatment period (T1); b) treatment period (T2).  Samples were taken from comparable 
times after the addition of the test substance in each treatment period.  Diamonds 
(SUHPs), crosses (RPs), squares (MUHPs), stars (LUHPs) and arrows (PBPs).  
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Figure 6.  
a. 
  
b. 
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Figure 7. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 + 
Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + Baclofen 
10-8 on SUHPs in the bath-applied method.  Control period BVC (C2). Data is 
reported as means and standard deviations (µ ±	 s.d).  * (significant differences).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88 
 
 
Figure 7.  
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Figure 8.  Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on XLUHPs in the bath-applied method.  Control period BVC (C2).  
Data is reported as means and standard deviations (µ ±	 s.d).  * (significant 
differences), ** (potentially significant differences).   
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Figure 8.  
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Figure 9. The bath-applied method effect on the GSH dose response for SUHPs, 
MUHPs and RPs.  Data is reported as mean and standard deviation (SUHPs, MUHPs) 
(µ ± s.d.) and means and standard error (RPs) (µ ± s.e).  Black diamonds (SUHPs), 
squares (MUHPs), white diamonds (RPs).    
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Figure 9.  
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Figure 10. The bath-applied method effect on the GSH dose response for LUHPs and 
XLUHPs.  Control is (C2) from bath-applied BVC.  Data is reported as mean and 
standard deviation (µ ± s.d.).  Stars (LUHPs) and circles (XLUHPs).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94 
 
 
Figure 10.  
 
 
 
 
 
 
 
 
 
 
 
 
 
0.1	  
1	  
10	  
100	  
1	   2	   3	  
Lo
g	  
(m
ea
n)
	  p
ul
se
	  
GSH	  5x10-­‐8	  (1),	  GSH	  5x10-­‐7	  (2),	  GSH	  5x10-­‐6	  (3)	  
LUHP	  	  
XLUHP	  	  
 95 
 
 
Figure 11. The bath-applied method effect on the GSH dose response for PBPs and 
P/PBPs.  Control is (C2) from bath-applied BVC.  Data is reported as mean and 
standard deviation (PBPs) (µ ± s.d.) and means and standard error (P/PBPs) (µ ± s.e).  
Black triangles (PBPs) and clear triangles (P/PBPs).      
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Figure 11. 
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Figure 12. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on MUHPs in the pipette-applied method.  Control period BVC (C1) 
(C2).  Data is reported as means and standard deviations (µ ±	 s.d). ** (potentially 
significant differences).   
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Figure 12.  
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Figure 13. The pipette-applied method effect on the GSH dose response for LUHPs 
and XLUHPs.  Control is (C1) and (C2) from bath-applied BVC.  Data is reported as 
mean and standard deviation (µ ± s.d.).  Stars (LUHPs) and circles (XLUHPs).   
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Figure 13. 
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Figure 14. The pipette-applied method effect on the GSH dose response for PBPs and 
P/PBPs.  Control is (C1) and (C2) from bath-applied BVC.  Data is reported as mean 
and standard deviation (PBPs) (µ ± s.d.) and means and standard error (P/PBPs) (µ ± 
s.e).  Black triangles (PBPs) and clear triangles (P/PBPs).       
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Figure 14. 
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Figure 15. The pipette-applied method effect on the GSH dose response for SUHPS, 
MUHPs and RPs.  Control is (C1) and (C2) from bath-applied BVC.  Data is reported 
as mean and standard deviation (SUHPs, MUHPs) (µ ± s.d.) and means and standard 
error (RPs) (µ ± s.e).  Black diamonds (SUHPs), squares (MUHPs) and white 
diamonds (RPs).    
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Figure 15.  
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Figure 16. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on MUHPs in the bath-applied method.  Control period BVC (C2).  
Data is reported as means and standard deviations (µ ±	 s.d).  * (significant 
differences), ** (potentially significant differences).   
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Figure 16.   
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Figure 17. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on LUHPs in the bath-applied method.  Control period BVC (C2).  Data 
is reported as means and standard deviations (µ ±	 s.d).  
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Figure 17.  
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Figure 18. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on PBPs in the bath-applied method.  Control period BVC (C2).  Data is 
reported as means and standard deviations (µ ±	 s.d).  
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Figure 18.  
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Figure 19. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on P/PBPs in the bath-applied method.  Control period BVC (C2).  Data 
is reported as means and standard error (µ ±	 s.e).   
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Figure 19.  
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Figure 20.  Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on RPs in the bath-applied method.  Control period BVC (C2).  Data is 
reported as means and standard error (µ ±	 s.e).  * (significant differences).  
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Figure 20.  
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Figure 21. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on LUHPs in the pipette-applied method.  Control period BVC (C1) 
(C2).  Data is reported as means and standard deviations (µ ±	 s.d).  * (significant 
differences), ** (potentially significant differences).    
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Figure 21.  
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Figure 22. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on P/PBPs in the pipette-applied method.  Control period BVC (C1) 
(C2).  Data is reported as means and standard error (µ ±	 s.e).  * (significant 
differences), ** (potentially significant differences).       
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Figure 22.  
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Figure 23.  Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on XLUHPs in the pipette-applied method.  Control period BVC (C1) 
(C2).  Data is reported as means and standard deviations (µ ±	 s.d).  * (significant 
differences). 
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Figure 23.  
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Figure 24. Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on RPs in the pipette-applied method.  Control period BVC (C1) (C2).  
Data is reported as means and standard error (µ ±	 s.e).  * (significant differences). 
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Figure 24.  
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Figure 25.  Sample recording with GSH 5x10-7 and GABA 10-6 in a) control (C2) 
bath-applied b) GSH 5x10-7 + GABA 10-6 (T2) bath-applied method c) control (C2) 
bath-applied method d) GSH 5x10-7 + GABA 10-6 pipette-applied method.  Diamonds 
(SUHPs), squares (MUHPs), stars (LUHPs) and arrows (PBPs).      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 124 
 
 
Figure 25.  
a. 
 
b.  
 
c.  
 
d. 
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Figure 26.  Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on SUHPs in the pipette-applied method.  Control period BVC (C1) 
(C2).  Data is reported as means and standard deviations (µ ±	 s.d).  * (significant 
differences), ** (potentially significant differences).   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 126 
 
 
Figure 26.  
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Figure 27:  Sample recording from the bath-applied and pipette-applied experiment. a) 
control period BVC (C2); b) treatment period (T1) with GSH 5x10-7M pipette-applied 
c) treatment period (T1) with GSH 5x10-7M + Baclofen 1x10-8M bath-applied d) 
treatment period (T1) with GSH 5x10-7M + Baclofen 1x10-8M pipette-applied .  
Samples were taken from equivalent times after the addition of the test substance in 
each period, and control period (C2). Diamonds (SUHPs), squares (MUHPs), stars 
(LUHPs), crosses (RPs) and arrows (PBPs).    
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Figure 27.  
a. 
 
b. 
 
c. 
 
d.  
 
 
 
 
 129 
 
 
Figure 28.  Log (mean) effects of GSH 5x10-7, GSH 5x10-7 + GABA 10-6, GSH 5x10-7 
+ Phaclofen 10-8, GSH 5x10-7 + Baclofen 10-8, GSH 5x10-7 + Phaclofen 10-8 + 
Baclofen 10-8 on PBPs in the pipette-applied method.  Control period BVC (C1) (C2).  
Data is reported as means and standard deviations (µ ±	 s.d). ** (potentially significant 
differences).   
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Figure 28.  
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Figure 29. Sample recording from the bath-applied and pipette-applied method. a) 
control period BVC (C2) b) treatment period (T2) with GSH 5x10-7M pipette-applied 
c) treatment period (T2) with GSH 5x10-7M + Phaclofen 1x10-8M bath-applied d) 
treatment period (T2) with GSH 5x10-7M + Phaclofen 1x10-8M pipette-applied. 
Samples were taken from equivalent times after the addition of the test substance in 
each period, and control period.  Diamonds (SUHPs), squares (MUHPs), stars 
(LUHPs), arrows (PBPs) and crosses (RPs).  
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Figure 29.  
 a. 
 
b. 
 
c. 
 
d. 
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Figure 30: Sample recording from the bath-applied method and the pipette-applied 
method. a) control period BVC (C2) b) treatment period (T2) with GSH 5x10-7 M 
pipette-applied c) treatment period (T2) with GSH 5x10-7 M + Baclofen 1x10-8M + 
Phaclofen 1x10-8M bath-applied d) treatment period (T2) with GSH 5x10-7 M + 
Baclofen 1x10-8M + Phaclofen pipette-applied.  Samples were taken from equivalent 
times after the addition of the test substance in each period, and control period.  
Diamonds (SUHPs), squares (MUHPs) and crosses (RPs).   
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Figure 30: 
a.  
  
b. 
 
c. 
 
d. 
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Figure 31:  Sample recording from the pipette-applied experiment. a) control period 
BVC (C2) b) treatment period (T2) with GSH 5x10-7. c) treatment period (T2) with 
GSH 5x10-7 + GABA 10-6 c) treatment period (T2) with GSH 5x10-7 + Baclofen 10-8 
d) treatment period (T2) with GSH 5x10-7M + Phaclofen 1x10-8M e) treatment period 
(T2) with GSH 5x10-7M + Baclofen 1x10-8M + Phaclofen 1x10-8M. Samples were 
taken from equivalent times after the addition of the test substance in each period, and 
control period (C2).  Diamonds (SUHPs), squares (MUHPs) and stars (LUHPs).  
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Figure 31.  
a. 
 
b. 
 
c. 
 
d. 
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APPENDIX: Raw Data 
 
GSH 5x10-6: Bath-Applied Method 
GSH	  5x10-­‐6M	  C2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   74	   8	   3	   0	   1	   13	   0	  2	   118	   0	   3	   10	   1	   10	   6	  3	   134	   6	   0	   1	   1	   8	   0	  4	   30	   0	   0	   0	   0	   0	   0	  5	   17	   0	   0	   0	   1	   7	   0	  6	   319	   0	   4	   21	   3	   9	   2	  7	   168	   1	   1	   6	   1	   18	   7	  Sum	   860	   15	   11	   38	   8	   65	   15	  
 GSH	  5x10-­‐6M	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   313	   21	   0	   1	   0	   0	   0	  2	   298	   9	   0	   1	   0	   0	   0	  3	   343	   13	   1	   0	   0	   0	   5	  4	   353	   15	   1	   0	   0	   0	   2	  5	   235	   21	   2	   2	   0	   0	   17	  6	   306	   1	   0	   2	   0	   0	   12	  7	   211	   2	   0	   8	   0	   0	   4	  Sum	   2059	   82	   4	   14	   0	   0	   40	  
 GSH	  5x10-­‐6M	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   117	   9	   2	   0	   0	   0	   2	  2	   225	   4	   0	   0	   0	   0	   0	  3	   148	   0	   0	   0	   0	   0	   2	  4	   102	   5	   5	   9	   2	   9.5	   8	  5	   243	   1	   4	   5	   0	   0	   7	  6	   322	   7	   0	   1	   0	   0	   17	  7	   275	   1	   0	   9	   0	   0	   8	  Sum	   1432	   27	   11	   24	   2	   9.5	   44	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GSH 5x10-6: Pipette-Applied Method 
GSH	  5x10-­‐6M	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   351	   6	   2	   0	   0	   0	   23	  2	   226	   2	   0	   0	   0	   0	   2	  3	   251	   2	   0	   0	   2	   3.5	   6	  4	   159	   1	   1	   1	   0	   0	   7	  5	   41	   4	   0	   0	   1	   4	   9	  6	   31	   11	   1	   2	   3	   9	   2	  7	   30	   0	   0	   0	   2	   5.5	   0	  Sum	   1089	   26	   4	   3	   8	   22	   49	  
 GSH	  5x10-­‐6M	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   424	   9	   8	   1	   0	   6.33	   21	  2	   256	   19	   0	   0	   2	   12.5	   4	  3	   331	   1	   0	   1	   0	   4.5	   3	  4	   144	   2	   0	   0	   0	   0	   8	  5	   35	   5	   0	   0	   2	   9	   6	  6	   28	   16	   0	   0	   2	   12	   7	  7	   24	   0	   0	   0	   2	   8.5	   0	  Sum	   1242	   52	   8	   2	   8	   52.83	   49	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GSH 5x10-7: Bath-Applied  
GSH	  5x10-­‐7M	  C2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   50	   1	   0	   8	   1	   7	   0	  2	   44	   1	   3	   4	   0	   0	   1	  3	   10	   3	   1	   1	   1	   5	   0	  4	   27	   2	   2	   6	   1	   10	   0	  5	   2	   0	   0	   0	   0	   0	   0	  6	   56	   1	   1	   5	   1	   4	   4	  7	   66	   3	   3	   4	   1	   8	   1	  8	   131	   1	   0	   2	   0	   0	   0	  Sum	   386	   12	   10	   30	   5	   34	   6	  
 GSH	  5x10-­‐7M	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   191	   1	   0	   12	   1	   12	   0	  2	   118	   8	   0	   2	   0	   0	   2	  3	   43	   3	   0	   0	   0	   0	   1	  4	   74	   0	   1	   3	   0	   0	   1	  5	   10	   0	   0	   0	   0	   0	   0	  6	   83	   5	   0	   5	   0	   0	   5	  7	   80	   2	   1	   4	   0	   0	   0	  8	   144	   7	   2	   3	   0	   0	   0	  Sum	   743	   26	   4	   29	   1	   12	   9	  
 GSH	  5x10-­‐7M	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   159	   0	   0	   11	   1	   12	   1	  2	   50	   18	   0	   0	   1	   21	   0	  3	   127	   10	   0	   0	   0	   0	   0	  4	   24	   2	   5	   1	   1	   8	   1	  5	   2	   6	   0	   0	   1	   6	   0	  6	   72	   5	   3	   0	   1	   6	   0	  7	   137	   7	   2	   2	   0	   0	   3	  8	   63	   0	   0	   0	   0	   0	   0	  Sum	   634	   48	   10	   14	   5	   53	   5	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GSH 5x10-7: Pipette-Applied 
GSH	  5x10-­‐7M	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   225	   11	   7	   0	   1	   12	   39	  2	   244	   8	   11	   5	   3	   10.67	   2	  3	   169	   1	   0	   18	   2	   9	   3	  4	   48	   16	   1	   20	   2	   17.5	   0	  5	   70	   17	   0	   0	   2	   11	   0	  6	   121	   9	   8	   7	   3	   8.67	   23	  7	   215	   16	   4	   40	   2	   20.5	   6	  Sum	   1092	   78	   31	   90	   15	   89.34	   73	  
 GSH	  5x10-­‐7M	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   215	   0	   0	   0	   0	   0	   40	  2	   91	   13	   4	   0	   3	   11.67	   1	  3	   264	   3	   13	   13	   2	   13	   1	  4	   82	   1	   2	   23	   1	   20	   1	  5	   108	   2	   3	   22	   2	   15.5	   4	  6	   83	   2	   5	   5	   0	   0	   28	  7	   162	   5	   0	   27	   1	   24	   6	  Sum	   1005	   26	   27	   90	   9	   84.17	   81	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GSH 5x10-8: Bath-Applied 
GSH	  5x10-­‐8M	  C2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   112	   0	   0	   12	   1	   12	   12	  2	   184	   6	   4	   7	   1	   14	   13	  3	   294	   6	   2	   25	   3	   10.6	   1	  4	   42	   0	   0	   0	   0	   0	   14	  5	   106	   21	   5	   6	   2	   12	   0	  6	   272	   6	   1	   17	   2	   8	   9	  7	   121	   7	   4	   6	   3	   8.6	   0	  8	   172	   2	   1	   8	   1	   9	   1	  Sum	   1303	   48	   17	   81	   13	   74.2	   50	  
 GSH	  5x10-­‐8M	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   253	   1	   0	   1	   0	   0	   1	  2	   98	   8	   0	   0	   0	   0	   8	  3	   348	   9	   2	   8	   2	   7	   1	  4	   36	   1	   0	   0	   0	   0	   1	  5	   91	   12	   1	   0	   1	   16	   0	  6	   127	   23	   1	   21	   2	   9.5	   1	  7	   174	   2	   0	   11	   1	   12	   1	  8	   261	   4	   1	   1	   0	   0	   0	  Sum	   1388	   60	   5	   42	   6	   44.5	   13	  
 GSH	  5x10-­‐8M	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   276	   0	   0	   0	   0	   0	   2	  2	   98	   1	   1	   16	   1	   12	   3	  3	   137	   4	   1	   11	   1	   11	   0	  4	   57	   0	   1	   0	   0	   0	   0	  5	   91	   13	   0	   0	   2	   6	   2	  6	   267	   18	   0	   15	   1	   12	   1	  7	   67	   0	   0	   1	   0	   0	   0	  8	   176	   1	   0	   0	   0	   0	   0	  Sum	   1169	   37	   3	   43	   5	   41	   8	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GSH 5x10-8: Pipette-Applied  
GSH	  5x10-­‐8M	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   360	   23	   6	   33	   1	   13	   1	  2	   38	   3	   0	   2	   4	   5.25	   4	  3	   62	   11	   1	   5	   3	   6.33	   1	  4	   80	   3	   4	   9	   3	   6.67	   1	  5	   26	   2	   2	   3	   1	   6	   1	  6	   215	   0	   0	   0	   0	   0	   4	  Sum	   781	   42	   13	   52	   12	   37.25	   12	  
 GSH	  5x10-­‐8M	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   64	   8	   1	   29	   2	   13.5	   1	  2	   18	   5	   1	   0	   1	   6	   1	  3	   34	   3	   1	   7	   2	   9.5	   1	  4	   108	   1	   2	   2	   1	   8	   3	  5	   39	   1	   0	   4	   1	   4	   1	  6	   167	   0	   0	   0	   0	   0	   4	  Sum	   430	   18	   5	   42	   7	   41	   11	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GSH + GABA: Bath-Applied 
GSH	  GABA	  C2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHPS	   PBP	   P/B	   RP	  1	   162	   7	   3	   11	   1	   18	   4	  2	   227	   30	   7	   8	   0	   0	   1	  3	   306	   1	   0	   4	   0	   0	   5	  4	   253	   12	   4	   15	   1	   14	   4	  5	   78	   1	   4	   7	   1	   10	   5	  6	   106	   2	   0	   2	   0	   0	   1	  7	   79	   12	   0	   0	   1	   11	   0	  8	   50	   1	   0	   8	   1	   9	   1	  Sum	   1261	   66	   18	   55	   5	   62	   21	  
 GSH	  GABA	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   169	   0	   3	   13	   1	   16	   6	  2	   185	   17	   2	   4	   0	   0	   1	  3	   391	   6	   3	   9	   1	   10	   4	  4	   390	   3	   0	   1	   0	   0	   6	  5	   94	   9	   7	   10	   1	   26	   0	  6	   127	   2	   1	   14	   1	   15	   1	  7	   49	   5	   8	   1	   1	   12	   0	  8	   84	   7	   0	   1	   0	   0	   2	  Sum	   1489	   49	   24	   53	   5	   79	   20	  
 GSH	  GABA	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   141	   1	   2	   16	   1	   19	   4	  2	   210	   0	   0	   2	   0	   0	   1	  3	   492	   0	   0	   0	   0	   0	   2	  4	   280	   22	   3	   2	   0	   0	   3	  5	   42	   1	   1	   0	   0	   0	   1	  6	   79	   1	   1	   2	   0	   0	   4	  7	   79	   1	   0	   0	   1	   10	   0	  8	   160	   8	   0	   0	   0	   0	   2	  Sum	   1483	   34	   7	   22	   2	   29	   17	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GSH + GABA: Pipette-Applied 
GSH	  GABA	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   235	   6	   1	   5	   2	   7	   12	  2	   154	   1	   1	   22	   4	   7	   10	  3	   256	   25	   15	   16	   1	   20	   13	  4	   365	   4	   1	   26	   2	   11	   3	  5	   147	   8	   3	   23	   3	   9.67	   9	  6	   277	   2	   2	   27	   2	   15	   2	  7	   141	   0	   0	   40	   3	   13.67	   3	  Sum	   1575	   46	   23	   159	   17	   83.34	   52	  
 GSH	  GABA	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   127	   1	   9	   8	   2	   8.5	   12	  2	   112	   0	   2	   19	   1	   15	   7	  3	   147	   13	   22	   3	   3	   13	   6	  4	   191	   2	   1	   24	   1	   25	   3	  5	   193	   6	   2	   19	   2	   19.5	   3	  6	   178	   1	   0	   16	   1	   16	   1	  7	   236	   0	   1	   16	   1	   16	   3	  Sum	   1184	   23	   37	   105	   11	   113	   35	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GSH + Phaclofen: Bath-Applied 
GSH	  Phaclofen	  C2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/PBP	   RP	  1	   115	   0	   0	   7	   0	   0	   6	  2	   103	   1	   2	   4	   2	   7	   2	  3	   46	   0	   11	   11	   2	   11	   1	  4	   260	   5	   0	   16	   1	   17	   8	  5	   171	   2	   0	   15	   2	   8	   10	  6	   162	   6	   0	   0	   1	   5	   27	  7	   120	   2	   0	   25	   1	   14	   5	  8	   147	   1	   0	   20	   1	   19	   2	  Sum	   1124	   17	   13	   98	   10	   81	   61	  
 GSH	  Phaclofen	  T1	  Trial	   SUHP	   MUHP	   LUHP	   	   PBP	   P/PBP	   RP	  1	   115	   0	   0	   19	   1	   14	   1	  2	   87	   2	   0	   7	   1	   9	   0	  3	   50	   2	   3	   16	   1	   12	   3	  4	   245	   7	   1	   0	   0	   0	   17	  5	   138	   0	   0	   14	   1	   15	   16	  6	   110	   1	   1	   2	   0	   0	   2	  7	   185	   2	   0	   23	   2	   11.5	   1	  8	   128	   1	   1	   3	   1	   15	   2	  Sum	   1058	   15	   6	   84	   7	   76.5	   42	  
 GSH	  Phaclofen	  T2	  Trial	   SUHP	   MUHP	   LUHP	   	   PBP	   P/PBP	   RP	  1	   91	   0	   0	   15	   1	   12	   0	  2	   73	   0	   1	   8	   2	   7.5	   1	  3	   52	   0	   0	   0	   0	   0	   2	  4	   88	   1	   0	   13	   1	   12	   10	  5	   86	   0	   2	   5	   0	   0	   9	  6	   81	   4	   2	   5	   1	   20	   3	  7	   133	   2	   0	   21	   2	   10.5	   2	  8	   76	   2	   4	   16	   1	   15	   0	  Sum	   680	   9	   9	   83	   8	   77	   27	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GSH + Phaclofen: Pipette-Applied 
GSH	  Phaclofen	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   320	   12	   5	   37	   1	   37	   9	  2	   260	   9	   19	   25	   2	   23	   0	  3	   133	   2	   9	   24	   4	   7.75	   2	  4	   200	   7	   1	   17	   3	   6.33	   2	  5	   93	   6	   0	   3	   0	   0	   6	  6	   103	   8	   5	   10	   2	   7.5	   5	  7	   205	   1	   0	   20	   3	   6.33	   3	  Sum	   1314	   45	   39	   136	   15	   87.91	   27	  
 GSH	  Phaclofen	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   204	   9	   4	   15	   1	   21	   12	  2	   195	   8	   14	   0	   1	   22	   1	  3	   74	   4	   7	   15	   2	   11	   0	  4	   294	   23	   5	   2	   0	   0	   0	  5	   194	   11	   2	   1	   0	   0	   0	  6	   131	   2	   1	   2	   0	   0	   2	  7	   130	   0	   0	   19	   2	   9.5	   4	  Sum	   1222	   57	   33	   54	   6	   63.5	   19	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GSH + Baclofen: Bath-Applied  
GSH	  Baclofen	  C1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   303	   4	   0	   0	   0	   0	   3	  2	   76	   7	   6	   11	   2	   9.5	   1	  3	   206	   8	   1	   14	   2	   11.5	   2	  4	   228	   3	   4	   15	   1	   16	   2	  5	   45	   1	   0	   0	   2	   16.5	   0	  6	   26	   0	   0	   0	   2	   5.5	   4	  7	   299	   34	   4	   3	   0	   0	   3	  8	   72	   1	   0	   0	   0	   0	   4	  9	   234	   3	   0	   0	   1	   17	   21	  10	   155	   3	   1	   16	   1	   10	   16	  11	   162	   8	   7	   5	   1	   8	   40	  Sum	   1806	   72	   23	   64	   12	   94	   96	  
 GSH	  BACLOFEN	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   350	   4	   1	   0	   0	   0	   1	  2	   207	   3	   3	   17	   2	   7	   0	  3	   93	   4	   2	   6	   1	   7	   2	  4	   217	   0	   0	   13	   0	   0	   2	  5	   59	   0	   0	   0	   4	   13.75	   0	  6	   28	   0	   0	   0	   0	   0	   0	  7	   237	   22	   4	   0	   0	   0	   13	  8	   39	   0	   0	   0	   1	   9	   5	  9	   127	   3	   5	   3	   1	   10	   0	  10	   166	   2	   1	   0	   0	   0	   8	  11	   127	   16	   1	   11	   2	   7.5	   16	  Sum	   1650	   54	   17	   50	   11	   54.25	   47	  
 GSH	  BACLOFEN	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   30	   3	   0	   2	   0	   0	   4	  2	   329	   47	   9	   2	   0	   0	   1	  3	   286	   2	   1	   0	   0	   0	   3	  4	   207	   3	   2	   4	   1	   4	   0	  5	   41	   0	   0	   0	   3	   11	   0	  6	   39	   0	   0	   0	   0	   0	   0	  7	   191	   17	   2	   10	   1	   11	   7	  8	   40	   2	   0	   0	   0	   0	   5	  9	   141	   0	   1	   5	   1	   12	   0	  10	   154	   2	   0	   0	   0	   0	   4	  11	   132	   3	   3	   16	   1	   15	   18	  Sum	   1590	   79	   18	   39	   7	   53	   42	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GSH + Baclofen: Pipette-Applied 
GSH	  Baclofen	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   66	   1	   1	   0	   0	   0	   2	  2	   91	   10	   5	   9	   3	   7.67	   3	  3	   38	   0	   1	   0	   0	   0	   8	  4	   86	   13	   2	   1	   3	   5.66	   4	  5	   93	   1	   2	   17	   3	   6	   2	  6	   64	   1	   0	   0	   0	   0	   1	  7	   39	   3	   0	   0	   0	   0	   10	  Sum	   477	   29	   11	   27	   9	   19.33	   30	  
 GSH	  Baclofen	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   48	   0	   0	   0	   0	   0	   2	  2	   50	   5	   8	   11	   2	   10.5	   1	  3	   26	   3	   0	   0	   3	   7.33	   8	  4	   64	   19	   2	   0	   3	   9	   0	  5	   31	   8	   3	   1	   1	   12	   1	  6	   31	   5	   5	   0	   2	   6	   3	  7	   56	   1	   0	   0	   0	   0	   8	  Sum	   306	   41	   18	   12	   11	   44.83	   23	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GSH + Baclofen + Phaclofen: Bath-Applied 
GSH	  PHAC	  BAC	  C2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHPS	   PBP	   P/B	   RP	  1	   69	   3	   1	   0	   0	   0	   11	  2	   142	   5	   1	   1	   0	   0	   5	  3	   114	   1	   0	   10	   1	   8	   5	  4	   100	   3	   1	   1	   0	   0	   16	  5	   241	   2	   0	   19	   2	   7	   4	  6	   127	   7	   0	   1	   0	   0	   8	  7	   238	   3	   1	   15	   1	   8	   14	  8	   116	   7	   1	   9	   1	   7	   7	  Sum	   1147	   31	   5	   56	   5	   30	   70	  
 GSH	  PHAC	  BAC	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHPS	   PBP	   P/B	   RP	  1	   71	   10	   0	   0	   1	   6	   10	  2	   165	   5	   2	   3	   0	   0	   6	  3	   178	   0	   0	   7	   0	   0	   0	  4	   82	   1	   0	   0	   0	   0	   4	  5	   142	   0	   0	   11	   1	   11	   5	  6	   155	   1	   0	   0	   0	   0	   3	  7	   160	   0	   0	   2	   0	   0	   18	  8	   165	   22	   2	   1	   0	   0	   1	  Sum	   1118	   39	   4	   24	   2	   17	   47	  
 GSH	  PHAC	  BAC	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHPS	   PBP	   P/B	   RP	  1	   118	   2	   1	   0	   0	   0	   4	  2	   85	   0	   0	   9	   1	   9	   4	  3	   37	   0	   0	   12	   1	   12	   0	  4	   9	   0	   0	   2	   0	   0	   2	  5	   84	   0	   0	   13	   1	   12	   1	  6	   178	   0	   0	   0	   0	   0	   0	  7	   328	   0	   1	   12	   1	   15	   12	  8	   251	   1	   0	   0	   0	   0	   2	  Sum	   1090	   3	   2	   48	   4	   48	   25	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GSH + Baclofen + Phaclofen: Pipette-Applied 
Phac	  Bac	  T1	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   246	   10	   10	   12	   2	   24	   0	  2	   92	   2	   0	   0	   1	   32	   8	  3	   253	   5	   5	   20	   3	   7.33	   3	  4	   36	   4	   0	   0	   2	   6.5	   3	  5	   47	   0	   0	   0	   2	   8.5	   9	  6	   53	   0	   5	   17	   2	   11	   0	  7	   42	   1	   8	   10	   2	   9.5	   0	  Sum	   769	   22	   28	   59	   14	   98.83	   23	  
 GSH	  Phac	  Bac	  T2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   47	   17	   18	   2	   1	   14	   7	  2	   62	   6	   1	   0	   1	   7	   6	  3	   116	   0	   0	   18	   2	   10.5	   2	  4	   37	   6	   12	   0	   1	   18	   0	  5	   68	   2	   0	   0	   2	   17	   6	  6	   27	   2	   3	   13	   2	   8.5	   2	  7	   17	   3	   5	   2	   1	   9	   0	  Sum	   374	   36	   39	   35	   10	   84	   23	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BVC: Pipette-Applied 
BVC	  C1	  	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/B	   RP	  1	   156	   6	   1	   15	   1	   15	   5	  2	   249	   0	   0	   12	   2	   8.5	   0	  3	   455	   12	   1	   15	   2	   9.5	   3	  4	   128	   9	   2	   5	   1	   8	   0	  5	   156	   6	   1	   15	   1	   15	   7	  6	   123	   2	   0	   8	   2	   4	   10	  7	   173	   9	   1	   8	   1	   5	   2	  Sum	   1440	   44	   6	   78	   10	   65	   27	  
 BVC	  C2	  Trial	   SUHP	   MUHP	   LUHP	   XLUHP	   PBP	   P/PBP	   RP	  1	   136	   4	   0	   20	   2	   10.5	   0	  2	   129	   0	   0	   18	   1	   10	   0	  3	   262	   2	   6	   11	   2	   8	   3	  4	   130	   11	   1	   8	   1	   8	   2	  5	   136	   4	   0	   20	   2	   10.5	   0	  6	   146	   0	   0	   8	   2	   4	   10	  7	   355	   0	   0	   0	   0	   0	   2	  Sum	   1294	   21	   7	   85	   10	   51	   17	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